0001104659-21-066181.txt : 20210514 0001104659-21-066181.hdr.sgml : 20210514 20210513203014 ACCESSION NUMBER: 0001104659-21-066181 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210514 DATE AS OF CHANGE: 20210513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NeuBase Therapeutics, Inc. CENTRAL INDEX KEY: 0001173281 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 465622433 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35963 FILM NUMBER: 21921545 BUSINESS ADDRESS: STREET 1: 700 TECHNOLOGY DRIVE CITY: PITTSBURGH STATE: PA ZIP: 15219 BUSINESS PHONE: 6464501790 MAIL ADDRESS: STREET 1: 700 TECHNOLOGY DRIVE CITY: PITTSBURGH STATE: PA ZIP: 15219 FORMER COMPANY: FORMER CONFORMED NAME: Ohr Pharmaceutical Inc DATE OF NAME CHANGE: 20090819 FORMER COMPANY: FORMER CONFORMED NAME: BBM HOLDINGS, INC. DATE OF NAME CHANGE: 20070402 FORMER COMPANY: FORMER CONFORMED NAME: PRIME RESOURCE INC DATE OF NAME CHANGE: 20020513 10-Q 1 tm2114120d1_10q.htm FORM 10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended March 31, 2021
Or

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from _____ to _____.

Commission File Number 333-88480

NEUBASE THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

Delaware	46-5622433
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

350 Technology Drive, Pittsburgh, PA 15219
(Address of principal executive offices and zip code)

(646) 450-1790
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	NBSE	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

As of May 12, 2021, 32,716,827 shares of the common stock, par value $0.0001, of the registrant were outstanding.

Table of Contents

PART I		1

ITEM 1.	FINANCIAL STATEMENTS	1

ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	15

ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	24

ITEM 4.	CONTROLS AND PROCEDURES	24

PART II		26

ITEM 1.	LEGAL PROCEEDINGS	26

ITEM 1A.	RISK FACTORS	27

ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	27

ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	27

ITEM 4.	MINE SAFETY DISCLOSURES	27

ITEM 5.	OTHER INFORMATION	27

ITEM 6.	EXHIBITS	28

SIGNATURES		29

-i-

PART I.

ITEM 1. FINANCIAL STATEMENTS

NeuBase Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(Unaudited)

	March 31,			September 30,
	2021			2020
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	24,246,752		$	31,992,283
Prepaid insurance		256,985			521,617
Other prepaid expenses and current assets		436,394			294,640
Total current assets		24,940,131			32,808,540

EQUIPMENT, net		1,652,510			1,166,934

OTHER ASSETS
Investment		578,742			323,557
Long-term prepaid insurance		48,416			145,250
Security deposit		253,565			-
Total other assets		880,723			468,807

TOTAL ASSETS	$	27,473,364		$	34,444,281

LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
Accounts payable	$	2,175,792		$	1,505,042
Accrued expenses and other current liabilities		1,130,343			555,883
Warrant liabilities		229,442			950,151
Insurance note payable		-			138,557
Total liabilities		3,535,577			3,149,633

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS’ EQUITY
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2021 and September 30, 2020		-			-
Common stock, $0.0001 par value; 250,000,000 shares authorized; 23,180,024 and 23,154,084 shares issued and outstanding as of March 31, 2021 and September 30, 2020, respectively		2,317			2,315
Additional paid-in capital		77,082,072			74,850,935
Accumulated deficit		(53,146,602	)		(43,558,602	)
Total stockholders’ equity		23,937,787			31,294,648

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	27,473,364		$	34,444,281

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

NeuBase Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited)

	Three Months ended March 31,						Six Months ended March 31,
	2021			2020			2021			2020
OPERATING EXPENSES
General and administrative	$	2,721,640		$	2,739,021		$	5,363,110		$	5,293,701
Research and development		3,174,129			1,616,009			5,194,053			2,843,695
TOTAL OPERATING EXPENSES		5,895,769			4,355,030			10,557,163			8,137,396

LOSS FROM OPERATIONS		(5,895,769	)		(4,355,030	)		(10,557,163	)		(8,137,396	)

OTHER INCOME (EXPENSE)
Interest expense		(6,460	)		(342	)		(16,197	)		(1,653	)
Interest income		9,466			-			9,466			-
Change in fair value of warrant liabilities		90,597			69,944			720,709			(624,190	)
Equity in losses on equity method investment		(36,127	)		(92,842	)		(61,539	)		(117,351	)
Other income (expense)		316,724			-			316,724			(3,230	)
Total other income (expense), net		374,200			(23,240	)		969,163			(746,424	)

NET LOSS	$	(5,521,569	)	$	(4,378,270	)	$	(9,588,000	)	$	(8,883,820	)

BASIC AND DILUTED LOSS PER SHARE	$	(0.24	)	$	(0.26	)	$	(0.41	)	$	(0.52	)

WEIGHTED AVERAGE SHARES OUTSTANDING:
BASIC AND DILUTED		23,179,646			17,075,875			23,176,877			17,073,765

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

NeuBase Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Statements of Stockholders’ Equity

For the Three and Six Months Ended March 31, 2021 and 2020

(Unaudited)

	Common Stock				Additional					Total
	Shares		Amount		Paid-In Capital		Accumulated Deficit			Stockholders’ Equity
Balance as of December 31, 2020		23,177,591	$	2,317	$	76,139,964	$	(47,625,033	)	$	28,517,248
Stock-based compensation expense		-		-		942,108		-			942,108
Issuance of restricted stock for services		2,433		-		-		-			-
Net loss		-		-		-		(5,521,569	)		(5,521,569	)
Balance as of March 31, 2021		23,180,024	$	2,317	$	77,082,072	$	(53,146,602	)	$	23,937,787


	Common Stock				Additional					Total
	Shares		Amount		Paid-In Capital		Accumulated Deficit			Stockholders’ Equity
Balance as of September 30, 2020		23,154,084	$	2,315	$	74,850,935	$	(43,558,602	)	$	31,294,648
Stock-based compensation expense		-		-		2,118,693		-			2,118,693
Issuance of restricted stock for services		4,364		-		-		-			-
Exercise of stock options		21,576		2		112,444		-			112,446
Net loss		-		-		-		(9,588,000	)		(9,588,000	)
Balance as of March 31, 2021		23,180,024	$	2,317	$	77,082,072	$	(53,146,602	)	$	23,937,787


	Common Stock				Additional					Total
	Shares		Amount		Paid-In Capital		Accumulated Deficit			Stockholders’ Equity
Balance as of December 31, 2019		17,077,873	$	1,708	$	37,705,984	$	(30,679,632	)	$	7,028,060
Stock-based compensation expense		-		-		1,339,410		-			1,339,410
Issuance of restricted stock for services		2,752		-		-		-			-
Net loss		-		-		-		(4,378,270	)		(4,378,270	)
Balance as of March 31, 2020		17,080,625	$	1,708	$	39,045,394	$	(35,057,902	)	$	3,989,200

	Common Stock				Additional					Total
	Shares		Amount		Paid-In Capital		Accumulated Deficit			Stockholders’ Equity
Balance as of September 30, 2019		17,077,873	$	1,708	$	36,201,758	$	(26,174,082	)	$	10,029,384
Stock-based compensation expense		-		-		2,843,636		-			2,843,636
Issuance of restricted stock for services		2,752		-		-		-			-
Net loss		-		-		-		(8,883,820	)		(8,883,820	)
Balance as of March 31, 2020		17,080,625	$	1,708	$	39,045,394	$	(35,057,902	)	$	3,989,200

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

NeuBase Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Six Months ended March 31,
	2021			2020
Cash flows from operating activities
Net loss	$	(9,588,000	)	$	(8,883,820	)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation		2,118,693			2,843,636
Change in fair value of warrant liabilities		(720,709	)		624,190
Depreciation and amortization		151,418			199,500
Loss on marketable security		15,006			-
Loss on disposal of fixed asset		-			3,230
Equity in losses on equity method investment		61,539			117,351
Gain on sale of intellectual property		(316,724	)		-
Changes in operating assets and liabilities
Prepaid insurance, other prepaid expenses and current assets		122,878			214,698
Long-term prepaid insurance		96,834			96,833
Security deposit		(253,565	)		-
Accounts payable		436,646			186,911
Accrued expenses and other current liabilities		574,460			340,288
Net cash used in operating activities		(7,301,524	)		(4,257,183	)
Cash flows from investing activities
Purchase of laboratory and office equipment		(402,890	)		(161,916	)
Purchase of marketable securities		(29,996,904	)		-
Sale of marketable securities		29,981,898			-
Net cash used in investing activities		(417,896	)		(161,916	)
Cash flows from financing activities
Principal payment of financed insurance		(138,557	)		(122,919	)
Proceeds from exercise of stock options		112,446			-
Net cash used in financing activities		(26,111	)		(122,919	)
Net decrease in cash and cash equivalents		(7,745,531	)		(4,542,018	)
Cash and cash equivalents, beginning of period		31,992,283			10,313,966
Cash and cash equivalents, end of period	$	24,246,752		$	5,771,948

Supplemental disclosure of cash flow information:
Cash paid for interest	$	10,400		$	1,668

Non-cash investing and financing activities:
Deferred offering costs, accrued but not yet paid	$	-		$	196,724
Purchases of laboratory and office equipment in accounts payable	$	234,104		$	-
Preferred shares in DepYmed received as consideration for sale of intellectual property	$	316,724		$	-

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

NeuBase Therapeutics, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

1. Organization and Description of Business

NeuBase Therapeutics, Inc. and subsidiaries (the “Company” or “NeuBase”) is developing a modular peptide-nucleic acid (“PNA”) antisense oligo (“PATrOL™”) platform to address genetic diseases, with a single, cohesive approach. The PATrOL™-enabled anti-gene therapies are designed to improve upon current genetic medicine strategies by combining the advantages of synthetic approaches with the precision of antisense technologies. NeuBase plans to use its platform to address diseases which have a genetic source, with an initial focus on Myotonic Dystrophy Type 1 (“DM1”) and Huntington’s Disease (“HD”), as well as other genetic disorders and cancer.

NeuBase is a pre-clinical-stage biopharmaceutical company and continues to develop its clinical and regulatory strategy with its internal research and development team with a view toward prioritizing market introduction as quickly as possible. NeuBase’s lead programs are NT0100 and NT0200.

The NT0100 program is a PATrOL™-enabled therapeutic program being developed to target the mutant expansion in the HD messenger ribonucleic acid (“mRNA”). The NT0100 program includes proprietary PNAs which have the potential to be highly selective for the mutant transcript vs. the wild-type transcribed allele and the expectation to be applicable for all HD patients as it directly targets the expansion itself, and has the potential to be delivered systemically. PATrOL™-enabled drugs also have the unique ability to open RNA secondary structures and bind to either the primary nucleotide sequences or the secondary and/or tertiary structures. NeuBase believes the NT0100 program addresses an unmet need for a disease which currently has no effective therapeutics that target the core etiology of the condition. NeuBase believes there is a large opportunity in the U.S. and European markets for drugs in this space.

The NT0200 program is a PATrOL™-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease mRNA. The NT0200 program includes several proprietary PNAs which have the potential to be highly selective for the mutant transcript versus the wild-type transcribed allele and the expectation to be effective for nearly all DM1 patients as it directly targets the expansion itself. NeuBase believes the NT0200 program addresses an unmet need for a disease which currently has no effective therapeutics that target the core etiology of the condition. NeuBase believes there is a large opportunity in the U.S. and European markets for drugs in this space.

2. Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended September 30, 2020 included in the Company’s Annual Report on Form 10-K (the “Annual Report”) filed with the Securities and Exchange Commission (“SEC”) on December 23, 2020. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated during the consolidation process. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The accompanying unaudited condensed consolidated financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. In the opinion of management, the accompanying unaudited condensed consolidated financial statements for the periods presented reflect all adjustments, consisting of only normal, recurring adjustments, necessary to fairly state the Company’s financial position, results of operations and cash flows. The unaudited condensed consolidated financial statements for the interim periods are not necessarily indicative of results for the full year. The preparation of these unaudited condensed consolidated financial statements requires the Company to make estimates and judgments that affect the amounts reported in the financial statements and the accompanying notes. The Company’s actual results may differ from these estimates under different assumptions or conditions.

NeuBase Therapeutics, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s unaudited condensed consolidated financial statements relate to the valuation of stock-based compensation, the fair value of warrant liabilities and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources.

The Company assesses and updates estimates each period to reflect current information, such as the economic considerations related to the impact that the novel coronavirus disease (“COVID-19”) could have on its significant accounting estimates (see Part II, Item 1A – Risk Factors—“Our operations may be adversely affected by the coronavirus outbreak, and we face risks that could impact our business” in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 for further discussion of the effect of the COVID-19 pandemic on the Company’s operations). Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.

Fair Value Measurements

Fair value measurements are based on the premise that fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the following three-tier fair value hierarchy has been used in determining the inputs used in measuring fair value:

Level 1 – Quoted prices in active markets for identical assets or liabilities on the reporting date.

Level 2 – Pricing inputs are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Pricing inputs are generally unobservable and include situations where there is little, if any, market activity for the investment. The inputs into the determination of fair value require management’s judgment or estimation of assumptions that market participants would use in pricing the assets or liabilities. The fair values are therefore determined using factors that involve considerable judgment and interpretations, including but not limited to private and public comparables, third-party appraisals, discounted cash flow models, and fund manager estimates.

Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Management’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange.

NeuBase Therapeutics, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

Marketable Securities

Marketable securities are classified as trading and are carried at fair value. The Company’s marketable securities consist of corporate bonds and highly liquid mutual funds and exchange-traded & closed-end funds which are valued at quoted market prices. The Company had no marketable securities as of March 31, 2021 and September 30, 2020.

Net Loss Per Share

Basic net loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the dilutive effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants and stock options that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.

The following potentially dilutive securities outstanding as of March 31, 2021 and 2020 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:

	As of March 31,
	2021		2020
Common stock purchase options		6,552,884		6,506,966
Unvested restricted stock		-		3,125
Common stock purchase warrants		820,939		715,939
		7,373,823		7,226,030

Recent Accounting Pronouncements

In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes” (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments- Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). This guidance introduces a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. ASU 2016-13 also provides updated guidance regarding the impairment of available-for-sale debt securities and includes additional disclosure requirements. The new guidance is effective for public business entities that meet the definition of a Smaller Reporting Company as defined by the Securities and Exchange Commission for interim and annual periods beginning after December 15, 2022. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.

NeuBase Therapeutics, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

3. Liquidity

The Company expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As a result, the Company will likely need to raise additional capital through one or more of the following: issuance of additional debt or equity, or complete a licensing transaction for one or more of the Company’s pipeline assets. Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these unaudited condensed consolidated financial statements were available to be issued. There can be no assurance that the Company will be successful in acquiring additional funding, that the Company’s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.

4. Other Prepaid Expenses and Other Current Assets

The Company’s prepaid expenses and other current assets consisted of the following:

	As of March 31,		As of September 30,
	2021		2020
Prepaid research and development expense	$	29,422	$	205,641
Prepaid rent		301,481		-
Other prepaid expenses and other current assets		105,491		88,999
Total	$	436,394	$	294,640

5. Equipment

The Company’s equipment consisted of the following:

	As of March 31,			As of September 30,
	2021			2020
Laboratory equipment	$	1,825,393		$	1,319,123
Office equipment		137,201			6,477
Total		1,962,594			1,325,600
Accumulated depreciation		(310,084	)		(158,666	)
Property, plant and equipment, net	$	1,652,510		$	1,166,934

Depreciation expense for the three months ended March 31, 2021 and 2020 was approximately $0.08 million and $0.03 million, respectively. Depreciation expense for the six months ended March 31, 2021 and 2020 was approximately $0.15 million and $0.05 million, respectively.

NeuBase Therapeutics, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

6. Investment

The Company owns common and preferred shares of DepYmed, Inc. (“DepYmed”), which in aggregate represents approximately 13% ownership of DepYmed. In addition, the Company is entitled to hold one of the six seats on DepYmed’s board of directors.

In February 2021, the Company sold certain intellectual property to DepYmed in exchange for shares of Series A-4 preferred stock. The Company recognized a gain of $0.3 million related to the sale, which was recorded in Other income (expense) on the Company’s unaudited condensed consolidated statement of operations for the three and six months ended March 31, 2021.

The Company accounts for its investment in DepYmed common shares using the equity method of accounting and records its proportionate share of DepYmed’s net income and losses in the accompanying unaudited condensed consolidated statements of operations. Equity in losses for the three months ended March 31, 2021 and 2020 were approximately $0.04 million and $0.1 million, respectively. Equity in losses for the six months ended March 31, 2021 and 2020 were approximately $0.06 million and $0.1 million, respectively.

The Company accounts for its investment in preferred shares of DepYmed at cost, less any impairment, as the Company determined the preferred stock did not have a readily determinable fair value.

As of March 31, 2021 and September 30, 2020, the carrying amount of the Company’s aggregate investment in DepYmed was $0.6 million and $0.3 million, respectively.

7. Accrued Expenses and Other Current Liabilities

The Company’s accrued expenses and other current liabilities consisted of the following:

	As of March 31,		As of September 30,
	2021		2020
Accrued compensation and benefits	$	153,688	$	88,527
Accrued consulting settlement		250,000		-
Accrued professional fees		167,829		241,755
Accrued research and development		217,701		41,313
Accrued franchise tax		79,088		155,865
Accrued patent expenses		258,331		24,716
Other accrued expenses		3,706		3,707
Total	$	1,130,343	$	555,883

8. Fair Value

The following tables present the Company’s fair value hierarchy for its warrant liabilities measured at fair value on a recurring basis at March 31, 2021 and September 30, 2020:

	Fair Value Measurements as of March 31, 2021
	(Level 1)		(Level 2)		(Level 3)		Total
Liabilities
Warrant liabilities	$	-		-		229,442	$	229,442

	Fair Value Measurements as of September 30, 2020
	(Level 1)		(Level 2)		(Level 3)		Total
Liabilities
Warrant liabilities	$	-		-		950,151	$	950,151

NeuBase Therapeutics, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

The fair value of the warrant liabilities were determined using the Black-Scholes option pricing model. The following assumptions were used in determining the fair value of the warrant liabilities:

	As of March 31,
	2021			2020
Remaining contractual term (years)		0.7 - 1.0			1.7 - 2.0
Common stock price volatility		69.5% - 71.4%			89.6% - 92.5%*
Risk-free interest rate		0.07	%		0.23	%
Expected dividend yield		-			-

During the three and six months ended March 31, 2021, the Company utilized its historical volatility in the valuation of warrant liabilities as it had sufficient trading history.

The change in fair value of the warrant liabilities for the three and six months ended March 31, 2021 and 2020 is as follows:

Fair value as of September 30, 2020	$	950,151
Change in fair value		(630,112	)
Fair value as of December 31, 2020		320,039
Change in fair value		(90,597	)
Fair value as of March 31, 2021	$	229,442

Fair value as of September 30, 2019	$	496,343
Change in fair value		694,134
Fair value as of December 31, 2019		1,190,477
Change in fair value		(69,944	)
Fair value as of March 31, 2020	$	1,120,533

As of March 31, 2021 and September 30, 2020, the carrying value of cash and cash equivalents, accounts payable and the insurance note payable approximate fair value due to the short-term nature of these instruments.

9. Stockholders’ Equity

Warrants

Below is a summary of the Company’s issued and outstanding warrants as of March 31, 2021:

Expiration date	Exercise Price		Warrants Outstanding
December 13, 2021	$	55.00		20,627
April 10, 2022		20.00		695,312
July 6, 2023		8.73		105,000
				820,939

NeuBase Therapeutics, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

	Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)
Outstanding as of September 30, 2020		820,939	$	19.44
Outstanding as of March 31, 2021		820,939		19.44		1.2
Exercisable as of March 31, 2021		820,939		19.44		1.2

10. Stock-Based Compensation

As of March 31, 2021, an aggregate of 4,709,277 shares of common stock were authorized under the Company’s 2019 Stock Incentive Plan (the “2019 Plan”), subject to an “evergreen” provision that will automatically increase the maximum number of shares of common stock that may be issued under the term of the 2019 Plan. As of March 31, 2021, 1,294,956 common shares were available for future grants under the 2019 Plan. As of March 31, 2021, 291,667 shares of common stock were authorized under the Company’s 2016 Consolidated Stock Incentive Plan (the “2016 Plan”) and 147,041 common shares were available for future grants under the 2016 Plan.

The Company recorded stock-based compensation expense in the following expense categories of its unaudited condensed consolidated statements of operations for the three and six months ended March 31, 2021 and 2020:

	Three Months ended March 31,				Six Months ended March 31,
	2021		2020		2021		2020
General and administrative	$	448,880	$	954,241	$	1,291,159	$	2,067,352
Research and development		493,228		385,169		827,534		776,284
Total	$	942,108	$	1,339,410	$	2,118,693	$	2,843,636

Stock Options

Below is a table summarizing the options issued and outstanding as of and for the six months ended March 31, 2021:

	Stock Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)		Total Aggregate Intrinsic Value
Outstanding at September 30, 2020		6,190,790		$	2.76
Granted		534,340			7.59
Exercised		(21,576	)		5.21
Forfeited		(150,670	)		5.68
Outstanding at March 31, 2021		6,552,884			3.08		8.1	$	29,219,357
Exercisable as of March 31, 2021		4,575,375			1.65		7.7	$	26,884,291

NeuBase Therapeutics, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

As of March 31, 2021, unrecognized compensation costs associated with the stock options of $4.8 million will be recognized over an estimated weighted-average amortization period of 1.3 years.

The weighted average grant date fair value of options granted during the six months ended March 31, 2021 and 2020 was $5.32 and $4.78, respectively.

Key assumptions used to estimate the fair value of the stock options granted during the six months ended March 31, 2021 and 2020 included:

	Six Months ended March 31,
	2021		2020
Expected term of options (years)		5.5 - 7.0		7.0
Expected common stock price volatility		83% - 83.3%		78% - 83.5%
Risk-free interest rate		0.6% - 1.3%		0.9% - 1.8%
Expected dividend yield		-		-

During the six months ended March 31, 2021, the Company granted a stock option to purchase 225,000 shares to a consultant in recognition of future service to the Company as an employee. The exercisability and vesting of the stock options are subject to the consultant’s effective date of employment with the Company, which has not yet occurred as of March 31, 2021, and as a result, the grant-date of such option has not occurred under GAAP. Therefore, the number and fair value of the shares subject to this option are not reflected in the table summarizing the options issued and outstanding as of and for the six months ended March 31, 2021 and did not have an impact on unrecognized compensation costs or the estimated weighted-average amortization period above as of March 31, 2021.

Restricted Stock

A summary of the changes in the unvested restricted stock during the six months ended March 31, 2021 is as follows:

	Unvested Restricted Stock			Weighted Average Grant Date Fair Value Price
Unvested as of September 30, 2020		-		$	-
Granted		4,364			9.17
Vested		(4,364	)		9.17
Unvested as of March 31, 2021		-			-

11. Commitments and Contingencies

Operating Leases

In October 2020, the Company entered into a ten-year lease agreement with annual escalating rental payments for approximately 14,189 square feet of office and laboratory space in Pittsburgh, Pennsylvania. The first and second amendments to the lease agreement were executed in December 2020 and April 2021, respectively (collectively with the lease agreement, referred to herein as the “Lease”). The leased premises will serve as the Company’s headquarters upon the commencement of the lease. The initial term of the Lease commenced on May 1, 2021. On such date, the Company is obligated to begin making rental payments, provided that the Company may be entitled to a rental credit for certain periods based on the date the Landlord delivers possession of the office space and biology lab within the leased premises to the Company and the date the landlord substantially completes tenant improvements. The initial term of the Lease will extend approximately ten years from delivery of the leased premises to the Company, unless earlier terminated in accordance with the lease. The Company has the right to extend the term of the Lease for an additional five-year term. The Company will pay an escalating base rent over the life of the Lease of approximately $71,000 to $78,000 per month, and the Company will pay its pro rata portion of property expenses and operating expenses for the property. The Company will measure and recognize the right-of-use (“ROU”) asset and operating lease liability upon lease commencement. During the six months ended March 31, 2021, the Company prepaid rent of $0.3 million and paid a security deposit of $0.3 million for this Lease.

NeuBase Therapeutics, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

The Company currently leases its existing office and operating space under operating leases with original terms of less than 12 months and which expire at various dates through November 2021; therefore, the Company’s operating leases are not recognized as ROU assets on the unaudited condensed consolidated balance sheet as of March 31, 2021.

Rent expense under the Company’s operating leases totaled approximately $0.03 million and $0.02 million for the three months ended March 31, 2021 and 2020, respectively. Rent expense under the Company’s operating leases totaled approximately $0.06 million and $0.04 million for the six months ended March 31, 2021 and 2020, respectively.

The Company continues to operate under its current operating lease in Pittsburgh on a month-to-month basis and will continue to operate under the lease until the Company completes the move into its new headquarters and laboratory space, which is expected to occur in June 2021. All terms and conditions remain the same from the current lease.

In November 2020, the Company extended the term of its rental of office space in New York until November 2021.

Litigation

The Company has become involved in certain legal proceedings and claims which arise in the normal course of business. The Company believes that an adverse outcome is unlikely, and it cannot reasonably estimate the potential loss at this point. If an unfavorable ruling were to occur, there exists the possibility of a material adverse impact on the Company’s results of operations, prospects, cash flows, financial position and brand.

On February 14, 2018, plaintiff Jeevesh Khanna, commenced an action in the Southern District of New York, against Ohr Pharmaceutical, Inc. (“Ohr”) (which was the name of the Company prior to the completion of the merger with NeuBase Therapeutics, Inc., a Delaware corporation (“Legacy NeuBase”), in accordance with the terms of the Agreement and Plan of Merger and Reorganization entered into on January 2, 2019, as amended, pursuant to which (i) Ohr Acquisition Corp., a subsidiary of Ohr, merged with and into Legacy NeuBase, with Legacy NeuBase (renamed as “NeuBase Corporation”) continuing as a wholly-owned subsidiary of Ohr and the surviving corporation of the merger and (ii) Ohr was renamed as “NeuBase Therapeutics, Inc.” (the “Merger”)) and several current and former officers and directors, alleging that they violated federal securities laws between June 24, 2014 and January 4, 2018. On August 7, 2018, the lead plaintiffs, now George Lehman and Insured Benefit Plans, Inc., filed an amended complaint, stating the class period to be April 8, 2014 through January 4, 2018. The plaintiffs did not quantify any alleged damages in their complaint but, in addition to attorneys’ fees and costs, they seek to maintain the action as a class action and to recover damages on behalf of themselves and other persons who purchased or otherwise acquired Ohr common stock during the putative class period and purportedly suffered financial harm as a result. We and the individuals dispute these claims and intend to defend the matter vigorously. On September 17, 2018, Ohr filed a motion to dismiss the complaint. On September 20, 2019, the district court entered an order granting the defendants’ motion to dismiss. On October 23, 2019, the plaintiffs filed a notice of appeal of that order dismissing the action and other related orders by the district court. After full briefing and oral argument, on October 9, 2020, the U.S. Court of Appeals for the Second Circuit issued a summary order affirming the district court’s order granting the motion to dismiss and remanding the action to the district court to make a determination on the record related to plaintiffs’ request for leave to file an amended complaint. On October 16, 2020, the district court requested the parties’ positions as to how they proposed to proceed in light of the Second Circuit’s decision. After letter briefing on this issue and plaintiffs’ alternative request for leave to file a second amended complaint, on November 16, 2020, the district court denied plaintiffs’ request to amend and dismissed with prejudice plaintiffs’ claims. On December 16, 2020, plaintiffs filed a notice of appeal of that order denying plaintiffs leave to amend. Briefing on the appeal is currently due in the first half of 2021. This litigation could result in substantial costs and a diversion of management’s resources and attention, which could harm the Company’s business and the value of the Company’s common stock.

On May 3, 2018, plaintiff Adele J. Barke, derivatively on behalf of Ohr, commenced an action against certain former directors of Ohr, including Michael Ferguson, Orin Hirschman, Thomas M. Riedhammer, June Almenoff and Jason S. Slakter in the Supreme Court, State of New York, alleging that the action was brought in the right and for the benefit of Ohr seeking to remedy their “breach of fiduciary duties, corporate waste and unjust enrichment that occurred between June 24, 2014 and the present.” It does not quantify any alleged damages. We and the individuals dispute these claims and intend to defend the matter vigorously. Such litigation has been stayed pursuant to a stipulation by the parties, which has been so ordered by the court, pending a decision in the Southern District case on the motion to dismiss, but that status could change. This litigation could result in substantial costs and a diversion of management’s resources and attention, which could harm our business and the value of our common stock.

NeuBase Therapeutics, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

On March 20, 2019, a putative class action lawsuit was filed in the United States District Court for District of Delaware naming as defendants Ohr and its board of directors, Legacy NeuBase and Ohr Acquisition Corp., captioned Wheby v. Ohr Pharmaceutical, Inc., et al., Case No. 1:19-cv-00541-UNA (the “Wheby Action”). The plaintiffs in the Wheby Action allege that the preliminary joint proxy/prospectus statement filed by Ohr with the SEC on March 8, 2019 contained false and misleading statements and omitted material information in violation of Section 14(a) of the Exchange Act and SEC Rule 14a-9 promulgated thereunder, and further that the individual defendants are liable for those alleged misstatements and omissions under Section 20(a) of the Exchange Act. The complaint in the Wheby Action has not been served on, nor was service waived by, any of the named defendants in that action. The action seeks, among other things, to rescind the Merger or an award of damages, and an award of attorneys’ and experts’ fees and expenses. The defendants dispute the claims raised in the Wheby Action. Management believes that the likelihood of an adverse decision from the sole remaining action is unlikely; however, the litigation could result in substantial costs and a diversion of management’s resources and attention, which could harm our business and the value of our common stock.

12. Subsequent Events

Common Stock Offering

On April 26, 2021, the Company closed an underwritten public offering of 9,200,000 shares of its common stock (inclusive of 1,200,000 shares that were sold pursuant to the underwriters’ full exercise of their option to purchase additional shares of the Company’s common stock), at a price to the public of $5.00 per share. The Company received net proceeds from the offering of approximately $42.6 million, after deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company.

Asset Purchase Agreement

On January 27, 2021, the Company entered into an Asset Purchase Agreement by and among the Company, NeuBase Corporation, its wholly owned subsidiary, and Vera Therapeutics, Inc. (“Vera”) as amended by the Amendment to Asset Purchase Agreement, dated as of April 20, 2021, by and between the Company and Vera (collectively, the “APA”) and the transaction closed on April 26, 2021. Pursuant to the terms of the APA, the Company acquired infrastructure, materials, and intellectual property for peptide-nucleic acid (“PNA”) scaffolds from Vera for total consideration of approximately $0.8 million in cash and 308,635 shares of common stock (of which 146,375 were to be issued to Vera and 162,260 will be held in escrow and released to Vera in accordance with the terms of an escrow agreement between NeuBase Corporation and Vera).

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Disclosures Regarding Forward-Looking Statements

The following should be read in conjunction with the unaudited condensed consolidated financial statements and the related notes that appear elsewhere in this report as well as in conjunction with the Risk Factors section in our Annual Report on Form 10-K for the fiscal year ended September 30, 2020 as filed with the United States Securities and Exchange Commission (“SEC”) on December 23, 2020. This report and our Form 10-K include forward-looking statements made based on current management expectations pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended.

This report includes “forward-looking statements” within the meaning of Section 21E of the Exchange Act. Those statements include statements regarding the intent, belief or current expectations of the Company and its subsidiaries and our management team. Any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ materially from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to those risks and uncertainties set forth in Part II, Item 1A – Risk Factors of this Quarterly Report and in Part I, Item 1A – Risk Factors of our Annual Report on Form 10-K. In light of the significant risks and uncertainties inherent in the forward-looking statements included in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K, the inclusion of such statements should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Further, these forward-looking statements reflect our view only as of the date of this report. Except as required by law, we undertake no obligations to update any forward-looking statements and we disclaim any intent to update forward-looking statements after the date of this report to reflect subsequent developments. Accordingly, you should also carefully consider the factors set forth in other reports or documents that we file from time to time with the SEC.

Overview

Recent Developments

December 2020 Announcement of Positive Preclinical Data

On December 16, 2020, we announced additional positive preclinical data on our platform and DM1 program. In vitro data highlights in DM1 patient-derived fibroblasts include activity of an anti-gene (Compound A) that targets the CUG repeat in DM1:

•

Compound A traffics to the nucleus, engages and normalizes DMPK mRNA.

•

Compound A begins induction of rescue of mis-splicing of two key DM1 dysregulated transcripts (MBNL1 and MBNL2) within two days after initial treatment. Notably, induction of rescue continues to improve through day 9, the latest time point analyzed.

•

Compound A significantly induces broad correction of global exon inclusion levels of mis-spliced transcripts.

○

Statistically significant improvement in global splicing as measured by the human differential splice inclusion (hDSI) statistic.

○

More than 175 dysregulated human transcripts achieved statistically significant improvement in splicing, many with completely normalized exon usage.

•

DMPK protein levels remain unchanged 5 days after a single Compound A dose, supporting the hypothesized mechanism of action maintaining DMPK.

In vivo data highlights in the HSA^LR transgenic mouse model of DM1 that expresses high levels of mutant CUG-repeat-containing mRNA (ACTA1) in skeletal muscle:

•

A single intravenous (IV) injection of 29 mg/kg of Compound A traffics to the nucleus and engages ACTA1 mRNA within 24 hours in tibialis anterior (TA) skeletal muscle.

•

A single intravenous (IV) injection of Compound A significantly induces broad correction of global exon inclusion levels of mis-spliced transcripts in HSA^LR TA skeletal muscle at day 13.

•

Statistically significant improvement in global splicing as measured by the murine differential splice inclusion (mDSI) statistic.

○

More than 50 unique dysregulated murine transcripts achieved statistically significant improvement in splicing post-treatment, with many achieving complete normalization of appropriate exon usage.

•

Compound A was well tolerated after single dose administration at the dose demonstrating activity in vivo.

Description of the Company

We are a biotechnology company working towards accelerating the genetic revolution by developing a new class of synthetic medicines. Our modular peptide-nucleic acid antisense oligo (“PATrOL™”) platform which outputs “anti-gene” candidate therapies is designed to combine the specificity of genetic sequence-based target recognition with a modularity that enables use of various in vivo delivery technologies to enable broad and also selective tissue distribution capabilities. Given that every human disease may have a genetic component, we believe that our differentiated platform technology has the potential for broad impact by increasing, decreasing or changing gene function at either the DNA or RNA levels to resolve the progression to disease, as appropriate, in a particular indication. We plan to use our platform to address diseases driven by genetic variation and mutation, and we are initially focused on myotonic dystrophy type 1 (“DM1”) and Huntington’s disease (“HD”).

Globally, there are thousands of genetic diseases, most of which lack any therapeutic options. In addition, rare genetic diseases are often particularly severe, debilitating or fatal. Traditionally, therapeutic development for each rare genetic disorder has been approached with a unique strategy, which is inefficient, as there are thousands of diseases that need treatment solutions. The collective population of people with rare diseases stands to benefit profoundly from the emergence of a scalable and modular treatment development platform that allows for a more efficient discovery and delivery of drug product candidates to address these conditions cohesively.

Mutated proteins resulting from errors in deoxyribonucleic acid (“DNA”) sequences cause many rare genetic diseases and cancer. DNA in each cell of the body is transcribed into pre-RNA, which is then processed (spliced) into mRNA which is exported into the cytoplasm of the cell and translated into protein. This is termed the “central dogma” of biology. Therefore, when errors in a DNA sequence occur, they are propagated to RNAs and can become a damaging protein.

The field has learned that antisense oligonucleotides (“ASOs”) can inactivate target RNAs before they can produce harmful proteins by binding them in a sequence-specific manner, which can delay disease progression or even eliminate genetic disease symptoms. ASOs designed by others to target known disease-related mutant RNA sequences have been shown to be able to degrade these transcripts and have a positive clinical impact. Similarly, applications in modifying splicing of pre-RNA in the nucleus of the cell have been developed by others to exclude damaging exons from the final mRNA product and have been approved by the Food and Drug Administration (“FDA”). We plan to extend upon these conceptual breakthroughs by utilizing our first-in-class technology which produces investigational therapies which are similar in structure to ASOs in that they are comprised of a backbone onto which are tethered nucleobases that engage a genetic sequence of interest using complementary base-pairing, but which we believe have significant benefits in certain application areas to better resolve clinical disorders.

We are developing “anti-gene” therapies. Anti-genes are similar to, but distinct from, antisense oligonucleotides (ASOs). ASOs are short single strands of nucleic acids (traditionally thought of as single-stranded DNA molecules) which bind to defective RNA targets in cells and inhibit their ability to form defective proteins. We believe we are a leader in the discovery and development of anti-gene therapies, a new class of investigational therapies derived from peptide-nucleic acids (“PNAs”). The key differentiator between ASOs and anti-genes is that the scaffold is not derived from a natural sugar-phosphate nucleic acid backbone, rather is a synthetic polyamide which is charge-neutral and characterized by high binding affinity to a nucleic acid target, high sequence specificity, high stability, and is relatively immunologically inert. These features provide potential advantages over ASOs and other genetic therapies for modulating disease-causing genes including increased unique disease target opportunities, improved target specificity and a reduction in both sequence-dependent and independent toxicities. In addition, as these anti-genes are manufactured via standard peptide synthesis methods, they efficiently leverage the advancements in the synthetic peptide industry to enable modulation of pharmacophore delivery, pharmacokinetics, sub-cellular placement and endosomal escape.

In addition to the scaffold, we have a kit of natural nucleobases, chemically modified nucleobases which add further precision to a nucleic acid target of interest, and proprietary bi-specific nucleobases (“janus” nucleobases) which can be added to the scaffold to enable more precise target engagement. These bi-specific nucleobases, in particular, have been shown to enable accessing double stranded RNA targets comprised of secondary structures such as hairpins (double stranded RNA targets which are folded upon themselves). This allows us to potentially access regions of the target transcript which may be unique in secondary structure to allow enhanced selectivity for the target (mutant) RNA as compared to the normal RNA. Enhanced selectivity for mutant RNAs as compared to normal RNAs is often important as normal RNAs are often required for effective functioning of the cell.

A third component of the modular platform is the ability to add delivery technology to the anti-gene pharmacophores so as to reach a desired cell or tissue upon in vivo administration. There is flexibility to append various delivery technologies to the pharmacophore to allow either broad tissue distribution or narrow cell and/or tissue targeting if so desired based on targets. One such technology is a chemical moiety that can be used to decorate the scaffold directly and allows the anti-genes to penetrate cell membranes and into subcellular compartments where they act as well as to distribute throughout the body when administered systemically.

Finally, in addition to the anti-gene scaffold, modified nucleobases and delivery technology, the platform toolkit also includes linker technology which, when added to both ends of the anti-genes, has been shown in early pre-clinical studies to allow cooperative binding between individual drug molecules once they are engaged with the nucleic acid target to form longer and more tightly bound drugs.

This toolkit of components forms the PATrOL™ platform and allows us to manufacture gene and transcript-specific anti-genes.

We are currently focused on therapeutic areas in which we believe our drugs will provide the greatest benefit with a significant market opportunity. We intend to utilize our technology to build a pipeline of custom designed therapeutics for additional high-value disease targets. We are developing several preclinical programs using our PATrOL™ platform, including the NT0100 program, targeted at Huntington’s disease, a repeat expansion disorder, and the NT0200 program, targeted at myotonic dystrophy, type 1, a second repeat expansion disorder. Preclinical studies are being conducted to evaluate the PATrOL™ platform technology and program candidates in the areas of pharmacokinetics, pharmacodynamics and tolerability, and we reported results from certain of those studies in the first calendar quarter of 2020 and have extended upon certain of those studies in the fourth calendar quarter of 2020 which illustrated that our anti-gene technology can be administered to human patient-derived cell lines and systemically (via intravenous (IV) administration) into animals with DM1 (a genetically modified model accepted as representative of the human disease in skeletal muscle) and can address the causal genetic defect. We expect to present additional results from ongoing preclinical studies evaluating the PATrOL^TM platform and pipeline indications in June 2021. In addition, we believe that the emerging pipeline of other investigational therapies that target primary and secondary RNA structure and genomic DNA potentially allows a unique market advantage across a variety of rare diseases and oncology targets.

Overall, using our PATrOL™ platform, we believe we can create anti-gene therapies that may have distinct advantages over other chemical entities currently in the market or in development for genetic medicine applications to modulate mutant genes and improve a clinical trait or disorder. These potential advantages may differ by indication and can include, among others:

•

increased unique target opportunities, improved target specificity and a reduction in both sequence-dependent and independent toxicities by virtue of a synthetic polyamide scaffold which is charge-neutral and characterized by high binding affinity to a nucleic acid target, high sequence specificity, high stability, and is relatively immunologically inert;

•

potential long durability by nature of the relatively highly stable polyamide scaffold;

•

our anti-genes are manufactured via standard peptide synthesis methods and thus they efficiently leverage advances in the synthetic peptide industry to enable facile addition of known moieties enabling modulating pharmacophore delivery, pharmacokinetics, sub-cellular placement and endosomal escape; and

•

our anti-genes may be able to target double stranded structures in RNA, which may allow unique target opportunities that standard ASOs cannot access.

With these unique component parts and their advantages, we believe our PATrOL™ platform-enabled anti-gene therapies can potentially address a multitude of rare genetic diseases and cancer, among other indications.

We employ a rational approach to selecting disease targets, considering many scientific, technical, business and indication-specific factors before choosing each indication. We intend to build a diverse portfolio of therapies to treat a variety of health conditions, with an initial emphasis on rare genetic diseases and cancers. A key component of this strategy is continuing to improve the scientific understanding and optimization of our platform technology and programs, including how various components of our platform technology perform, and how our investigational therapies impact the biological processes of the target diseases, so that we can utilize this information to reduce risk in our future programs and indications. In addition, with our expertise in discovering and characterizing novel anti-gene investigational therapies, we believe that our scientists can optimize the properties of our PATrOL™-enabled drug candidates for use with particular targets that we determine to be of high value.

We believe the depth of our knowledge and expertise with PNAs, engineered nucleotides, genetics and genomics and therapeutic development of first-in-class modalities provides potential flexibility to determine the optimal development and commercialization strategy to maximize the near and longer-term value of our therapeutic programs.

We plan to employ distinct partnering strategies based on the specific drug candidate, therapeutic area expertise and resources potential partners may bring to a collaboration. For some drug candidates, we may choose to develop and, if approved, commercialize them ourselves or through our affiliates. For other drug candidates, we may form single or multi-asset partnerships leveraging our partners’ global expertise and resources needed to support large commercial opportunities.

We believe the breadth of the PATrOL™ platform gives us the ability to potentially address a multitude of inherited genetic diseases. The technology may allow us to target and inactivate gain-of-function and change-of-function mutations, and address targets in recessive disease and haploinsufficiencies by altering splicing to remove damaging exons/mutations or increasing expression of wild-type alleles by various means.

Modified scaffolds, optimized versions of traditional PNA scaffolds which we utilize, have demonstrated preclinical in vivo efficacy in several applications which we believe can be translated across many targets and into humans. For example, in oncology such scaffolds have reduced expression of an activated oncogene (the epidermal growth factor receptor of the EGFR gene) and have modified gene regulation by targeting microRNA to slow tumor growth. Such scaffolds have also demonstrated in vivo engagement with the double-stranded genome in studies done by others to perform in vivo single-base genome editing.

Product Pipeline

NT0100 Program - PATrOL™ Enabled Anti-Gene for Huntington’s Disease

HD is a devastating rare neurodegenerative disorder. After onset, symptoms such as uncontrolled movements, cognitive impairments and emotional disturbances worsen over time. HD is caused by toxic aggregation of mutant huntingtin protein, leading to progressive neuron loss in the striatum and cortex of the brain. The wild-type huntingtin gene (HTT) has a region in which a three-base DNA sequence, CAG, is repeated many times. When the DNA sequence CAG is repeated 26 or fewer times in this region, the resulting protein behaves normally. While the normal or wild-type function of HTT protein is largely uncharacterized, it is known to be essential for normal brain development. When the DNA sequence CAG is repeated 40 times or more in this region, the resulting protein becomes toxic and causes HD. Every person has two copies, or alleles, of the HTT gene. Only one of the alleles (the “mutant” allele) needs to bear at least 40 CAG repeats for HD to occur. HD is one of many known repeat expansion disorders, which are a set of genetic disorders caused by a mutation that leads to a repeat of nucleotides exceeding the normal threshold. Current therapies for patients with HD can only manage individual symptoms. There is no approved therapy that has been shown to delay or halt disease progression. There are approximately 30,000 symptomatic patients in the U.S. and more than 200,000 at-risk of inheriting the disease globally.

One especially important advantage of the PATrOL™ platform that makes it promising for the treatment of repeat expansion disorders like HD is the ability of our small anti-genes to potentially target the RNA hairpin. This allows our therapies to potentially inactivate mutant HTT mRNA before it can be translated into a harmful protein via selective binding to the expanded CAG repeats while leaving the normal HTT mRNA largely unbound to drug and producing functional protein. Achieving mutant allele selectivity would be a key advantage for any RNA-based approach aiming to treat HD. In March of 2020, we illustrated the ability of our anti-gene technology to enrich for translational inhibition and resultant reduction of mutant protein formation in human patient-derived cell lines versus wild-type protein production. We illustrated that our anti-genes can inhibit ribosomal elongation via high-affinity binding to a target RNA.

The PATrOL™-enabled NT0100 program is currently in preclinical development for the treatment of HD. We expect to initiate scale up and toxicology activities in calendar year 2022, with a target IND filing in calendar year 2023.

NT0200 Program- PATrOL™ Enabled Anti-Gene for Myotonic Dystrophy Type 1

Our pipeline also contains a second potentially transformative medicine, which we believe has significant potential for Myotonic dystrophy, type 1, a severe dominantly inherited genetic disease. DM1 is characterized clinically by myotonia (an inability to relax a muscle after contraction), muscle weakness and wasting, cardiac conduction defects and cognitive deficits. DM1 is caused by an expansion of a CUG trinucleotide repeat in the 3’ untranslated region (“UTR”), a noncoding region of the myotonic dystrophy protein kinase gene (DMPK) transcript. Diagnosis is confirmed by molecular genetic testing of the length of a trinucleotide repeat expansion. Repeat length exceeding 34 repeats is abnormal and often patients have hundreds or thousands of repeat units. Molecular genetic testing detects pathogenic variants in nearly 100% of affected individuals. It is estimated that the global prevalence of DM1 is approximately 1 in 20,000 individuals. Our recent data illustrates that we are able to systemically deliver our anti-genes intravenously in a DM1 genetic mouse model, engage the target in the skeletal muscles of the animals, and induce rescue of the causal splice defects.

The trinucleotide repeat expansion in the transcript causes disease by forming an aberrant hairpin structure in the nucleus of patient cells that captures and sequesters proteins that have critical functions in the nucleus related to appropriate splicing of hundreds of transcripts. These sequestered proteins cannot then fulfill their normal functions. In addition, it has been documented that sequestration of the mutant DMPK transcripts in the nucleus results in their inability to be translated and potentially results in haploinsufficiency, a situation where 50% of the protein in not enough to maintain normal function. Mice with both copies of their Dmpk gene knocked out manifest a cardiac conduction defect (Berul CI, Maguire CT, Aronovitz MJ, Greenwood J, Miller C, Gehrmann J, Housman D, Mendelsohn ME, Reddy S. Dpmk dosage alterations result in atrioventricular conduction abnormalities in a mouse myotonic dystrophy model. J Clin Invest. 1999 Feb;103(4):R1-7. doi: 10.1172/JCI5346. PMID: 10021468; PMCID: PMC408103.) and a CNS phenotype characterized by abnormal long-term potentiation (Schulz PE, McIntosh AD, Kasten MR, Wieringa B, Epstein HF. A role for myotonic dystrophy protein kinase in synaptic plasticity. J Neurophysiol. 2003 Mar;89(3):1177-86. doi: 10.1152/jn.00504.2002. Epub 2002 Nov 13. PMID: 12612014.) hypothesized to be due to inappropriate cytoskeletal remodeling. We propose that our mechanism of action is via direct engagement of our anti-gene with the expanded CUG repeat hairpin structure in the 3’ UTR of the mutant transcript, invasion and opening of the hairpin structure, and release of the sequestered CUG-repeat binding proteins. This release of sequestered proteins which are normally involved in developmentally appropriate pre-mRNA splicing in the nucleus resolves the generalized splice defect and thus the major causal event. Our DM1 anti-gene is designed to not specifically degrade the mutant transcript, rather to release these RNA-protein aggregates through steric displacement, which could also resolve any potential haploinsufficiency and as a result may improve endophenotypes of the clinical condition, such as in the heart and brain (contingent on delivering effective concentrations of anti-gene to these tissues).

The PATrOL™-enabled NT0200 program is currently in preclinical development for the treatment of DM1. We expect to initiate scale up and toxicology activities beginning in the middle of calendar year 2021, with an IND filing planned during calendar year 2022.

Additional Indications

In addition, we are in the process of building an early stage pipeline of other therapies that focus on the unique advantages of our technology across a variety of diseases with an underlying genetic driver.

Critical Accounting Estimates and Policies

The preparation of financial statements in accordance with United States generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in our unaudited condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience, market and other conditions, and various other assumptions it believes to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact us in the future, the estimation process is, by its nature, uncertain given that estimates depend on events over which we may not have control. If market and other conditions change from those that we anticipate, our unaudited condensed consolidated financial statements may be materially affected. In addition, if our assumptions change, we may need to revise our estimates, or take other corrective actions, either of which may also have a material effect in our unaudited condensed consolidated financial statements. We review our estimates, judgments, and assumptions used in our accounting practices periodically and reflect the effects of revisions in the period in which they are deemed to be necessary. We believe that these estimates are reasonable; however, our actual results may differ from these estimates.

Our critical accounting policies and estimates are discussed in our Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and there have been no material changes to such policies or estimates during the six months ended March 31, 2021.

Recent Accounting Pronouncements

Please refer to Note 2, Significant Accounting Policies—Recent Accounting Pronouncements, in Item 1, Financial Statements, for a discussion of recent accounting pronouncements.

Results of Operations

Results of operations for the quarter ended March 31, 2021 reflect the following changes from the quarter ended March 31, 2020:

	Three Months ended March 31,
	2021			2020			Change
OPERATING EXPENSES
General and administrative	$	2,721,640		$	2,739,021		$	(17,381	)
Research and development		3,174,129			1,616,009			1,558,120
TOTAL OPERATING EXPENSES		5,895,769			4,355,030			1,540,739
LOSS FROM OPERATIONS		(5,895,769	)		(4,355,030	)		(1,540,739	)
OTHER INCOME (EXPENSE)
Interest expense		(6,460	)		(342	)		(6,118	)
Interest income		9,466			-			9,466
Change in fair value of warrant liabilities		90,597			69,944			20,653
Equity in losses on equity method investment		(36,127	)		(92,842	)		56,715
Other income		316,724			-			316,724
Total other expenses, net		374,200			(23,240	)		397,440
NET LOSS	$	(5,521,569	)	$	(4,378,270	)	$	(1,143,299	)

During the quarter ended March 31, 2021, our operating loss increased by $1.5 million compared to the quarter ended March 31, 2020. Our net loss increased by $1.1 million for the quarter ended March 31, 2021, as compared to the quarter ended March 31, 2020. Until we are able to generate revenue from product sales, our management expects to continue to incur net losses.

General and Administrative Expenses

General and administrative expenses consist primarily of legal and professional fees, wages, stock-based compensation and insurance. General and administrative expenses decreased by $0.02 million for the quarter ended March 31, 2021, as compared to the quarter ended March 31, 2020, primarily due to decreases in stock-based compensation expense, accounting and legal costs, offset by increases in patent fees, settlement costs, professional fees, and employee head count.

Research and Development Expenses

Research and development expenses consist primarily of professional fees, research, development, and manufacturing expenses, and wages and stock-based compensation. Research and development expenses increased by $1.6 million for the quarter ended March 31, 2021, as compared to the quarter ended March 31, 2020, primarily due to increases in manufacturing expenses, employee head count, the ramp up of research and development activities and professional fees.

Change in Fair Value of Warrant Liabilities

Change in fair value of warrant liabilities reflects the changes in the fair value of outstanding warrants which is primarily driven by changes in our stock price. We recognized a gain of $0.09 million from the change in fair value of warrant liabilities for the quarter ended March 31, 2021, as compared to a gain of $0.07 million for the quarter ended March 31, 2020.

Equity in Losses on Equity Method Investment

We account for our investment in DepYmed common shares using the equity method of accounting and record our proportionate share of DepYmed’s net income and losses. Equity in losses was $0.04 million for the quarter ended March 31, 2021, as compared to $0.09 million for the quarter ended March 31, 2020.

Other Income

We recognized other income of $0.3 million during the quarter ended March 31, 2021 related to the sale of certain intellectual property to DepYmed in exchange for shares of Series A-4 preferred stock. There was no other income recognized during the quarter ended March 31, 2020.

Results of operations for the six months ended March 31, 2021 reflect the following changes from the six months ended March 31, 2020:

	Six Months ended March 31,
	2021			2020			Change
OPERATING EXPENSES
General and administrative	$	5,363,110		$	5,293,701		$	69,409
Research and development		5,194,053			2,843,695			2,350,358
TOTAL OPERATING EXPENSES		10,557,163			8,137,396			2,419,767
LOSS FROM OPERATIONS		(10,557,163	)		(8,137,396	)		(2,419,767	)
OTHER INCOME (EXPENSE)
Interest expense		(16,197	)		(1,653	)		(14,544	)
Interest income		9,466			-			9,466
Change in fair value of warrant liabilities		720,709			(624,190	)		1,344,899
Equity in losses on equity method investment		(61,539	)		(117,351	)		55,812
Other income (expense)		316,724			(3,230	)		319,954
Total other expenses, net		969,163			(746,424	)		1,715,587
NET LOSS	$	(9,588,000	)	$	(8,883,820	)	$	(704,180	)

During the six months ended March 31, 2021, our operating loss increased by $2.4 million compared to the six months ended March 31, 2020. Our net loss increased by $0.7 million for the six months ended March 31, 2021, as compared to the six months ended March 31, 2020. Until we are able to generate revenue from product sales, our management expects to continue to incur net losses.

General and Administrative Expenses

General and administrative expenses consist primarily of legal and professional fees, wages, stock-based compensation and insurance. General and administrative expenses increased by $0.07 million for the six months ended March 31, 2021, as compared to the six months ended March 31, 2020, primarily due to increases in patent fees, professional fees, settlement costs, and employee head count, and mostly offset by decreases in stock-based compensation and accounting expenses.

Research and Development Expenses

Research and development expenses consist primarily of professional fees, research, development, and manufacturing expenses, and wages and stock-based compensation. Research and development expenses increased by $2.4 million for the six months ended March 31, 2021, as compared to the six months ended March 31, 2020, primarily due to increases in manufacturing expenses, employee head count, and the ramp up of research and development activities.

Change in Fair Value of Warrant Liabilities

Change in fair value of warrant liabilities reflects the changes in the fair value of outstanding warrants which is primarily driven by changes in our stock price. We recognized a gain of $0.7 million from the change in fair value of warrant liabilities for the six months ended March 31, 2021, as compared to a loss of $0.6 million for the six months ended March 31, 2020.

Equity in Losses on Equity Method Investment

We account for our investment in DepYmed common shares using the equity method of accounting and record our proportionate share of DepYmed’s net income and losses. Equity in losses was $0.06 million for the six months ended March 31, 2021, as compared to $0.1 million for the six months ended March 31, 2020.

Other Income (Expense)

We recognized other income of $0.3 million during the six months ended March 31, 2021 related to the sale of certain intellectual property to DepYmed in exchange for shares of Series A-4 preferred stock. There was an immaterial amount of other expense recognized during the six months ended March 31, 2020.

Liquidity, Capital Resources and Financial Condition

We have had no revenues from product sales and have incurred operating losses since inception. As of March 31, 2021, we had an accumulated deficit of $53.1 million. We have historically funded our operations through the sale of common stock and the issuance of convertible notes and warrants. We received $33.3 million in net proceeds from our follow-on underwriting public offering of common stock in April 2020 and $42.6 million in net proceeds from our April 2021 follow-on underwriting public offering of common stock.

We expect to continue to incur significant operating losses for the foreseeable future and may never become profitable. As a result, we will likely need to raise additional capital through one or more of the following: the issuance of additional debt or equity or the completion of a licensing transaction for one or more of our pipeline assets.

Net working capital decreased from September 30, 2020 to March 31, 2021 by $8.3 million (to $21.4 million from $29.7 million). Our quarterly cash burn has increased compared to prior periods due to increased research and development and corporate activities and we expect it to continue to increase in future periods. We expect that our existing cash and cash equivalents, together with expected and committed cash from our existing collaboration, will be sufficient to fund our operations for at least the next twelve months and into calendar 2023. We have based this expectation on assumptions that may prove to be incorrect, and we may use our available capital resources sooner than we currently expect. In addition, we may elect to raise additional funds before we need them if the conditions for raising capital are favorable due to market conditions or strategic considerations, even if we expect we have sufficient funds for our current or future operating plans.

At present, we have no bank line of credit or other fixed source of capital reserves. Should we need additional capital in the future, we will be primarily reliant upon a private or public placement of our equity or debt securities, or a strategic transaction, for which there can be no warranty or assurance that we may be successful in such efforts. If we are unable to maintain sufficient financial resources, our business, financial condition and results of operations will be materially and adversely affected. This could affect future development and business activities and potential future clinical studies and/or other future ventures. Failure to obtain additional equity or debt financing will have a material, adverse impact on our business operations. There can be no assurance that we will be able to obtain the needed financing to achieve our goals on acceptable terms or at all.

Cash Flow Summary

The following table summarizes selected items in our unaudited condensed consolidated statements of cash flows:

	Six Months ended March 31,
	2021			2020
Net cash used in operating activities	$	(7,301,524	)	$	(4,257,183	)
Net cash used in investing activities		(417,896	)		(161,916	)
Net cash used in financing activities		(26,111	)		(122,919	)
Net decrease in cash and cash equivalents	$	(7,745,531	)	$	(4,542,018	)

Operating Activities

Net cash used in operating activities was approximately $7.3 million for the six months ended March 31, 2021, as compared to approximately $4.3 million for the six months ended March 31, 2020. Net cash used in operating activities in the six months ended March 31, 2021 was primarily the result of our net loss, the change in the fair value of warrant liabilities, gain on sale of intellectual property and cash used for the security deposit and prepayment of rent under our new operating lease for office and laboratory space, offset by our stock-based compensation expense and increases in accounts payable and accrued expenses. Net cash used in operating activities in the six months ended March 31, 2020 was primarily the result of our net loss, offset by our stock-based compensation expense and the change in fair value of warrant liabilities.

Investing Activities

Net cash used in investing activities was approximately $0.4 million for the six months ended March 31, 2021, as compared to $0.2 million for the six months ended March 31, 2020. Net cash used in investing activities for both periods was primarily the result of purchases of laboratory equipment.

Financing Activities

Net cash used in financing activities was approximately $0.03 million for the six months ended March 31, 2021, as compared to $0.1 million for the six months ended March 31, 2020. Net cash used in financing activities for the six months ended March 31, 2021 reflects the principal payments of financed insurance, and net proceeds from the exercise of stock options. Net cash used in financing activities for the six months ended March 31, 2021 reflects the principal payments of financed insurance.

Off-Balance Sheet Arrangements

As of March 31, 2021, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company, as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and are not required to provide the information required under this item.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2021. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of March 31, 2021, our disclosure controls and procedures were effective to provide reasonable assurance that the information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting during the quarterly period ended March 31, 2021.

PART II.

ITEM 1. LEGAL PROCEEDINGS

We have become involved in certain legal proceedings and claims which arise in the normal course of business. If an unfavorable ruling were to occur, there exists the possibility of a material adverse impact on our results of operations, prospects, cash flows, financial position and brand.

ITEM 1A. RISK FACTORS

We operate in a dynamic and rapidly changing environment that involves numerous risks and uncertainties. Certain factors may have a material adverse effect on our business, prospects, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, in addition to other information contained in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed under the caption “Risk Factors” that appear in Item 1A of our Annual Report on Form 10-K for the year ended September 30, 2020, filed with the U.S. Securities and Exchange Commission (“SEC”) on December 23, 2020. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations. There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended September 30, 2020.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Not applicable.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

ITEM 6. EXHIBITS

		Incorporated by Reference
Exhibit Number	Description	Form	File Number	Filing Date	Exhibit
2.1+	Agreement and Plan of Merger and Reorganization, dated as of January 2, 2019, by and among Ohr Pharmaceutical, Inc., Ohr Acquisition Corp. and NeuBase Therapeutics, Inc.	8-K	001-35963	1/3/2019	2.1

2.2	First Amendment to the Agreement and Plan of Merger and Reorganization, dated as of June 27, 2019, by and among Ohr Pharmaceutical, Inc., Ohr Acquisition Corp. and NeuBase Therapeutics, Inc.	8-K	001-35963	7/3/2019	2.1

3.1	Amended and Restated Certificate of Incorporation of the Company.	8-K	001-35963	7/12/2019	3.1

3.2	Amended and Restated Bylaws of the Company.	8-K	001-35963	9/23/2019	3.1

4.2	Form of Series A Warrant issued to investors pursuant to the Securities Purchase Agreement, dated December 7, 2016, by and among Ohr Pharmaceutical, Inc. and the purchasers listed therein.	8-K	001-35963	12/8/2016	4.1

4.3	Form of Warrant issued to investors pursuant to the Securities Purchase Agreement, dated as of April 5, 2017, by and among Ohr Pharmaceutical, Inc. and the purchasers listed therein.	8-K	001-35963	4/6/2017	4.1

4.4	Form of Common Stock Certificate.	S-8	333-233346	8/16/2019	4.17

31.1^*	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2^*	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1^*	Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes Oxley Act of 2002.

101.INS*	XBRL Instance Document.
101.SCH*	XBRL Taxonomy Extension Schema Document.
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document.

Filed herewith.

Management compensatory plan or arrangement.

+ All schedules and exhibits to the agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	NeuBase Therapeutics, Inc.

Date: May 13, 2021	/s/ Sam Backenroth
	Sam Backenroth
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-31.1 2 tm2114120d1_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Dietrich Stephan, Ph.D., certify that:

I have reviewed this Quarterly Report on Form 10-Q of NeuBase Therapeutics, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 13, 2021

By:

/s/ Dietrich Stephan

Dietrich Stephan, Ph.D.

President and Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 tm2114120d1_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Sam Backenroth, certify that:

I have reviewed this Quarterly Report on Form 10-Q of NeuBase Therapeutics, Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 13, 2021

By:

/s/ Sam Backenroth

Sam Backenroth

Chief Financial Officer

(Principal Financial Officer)

EX-32.1 4 tm2114120d1_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of NeuBase Therapeutics, Inc. (the “Company”) for the period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to their knowledge that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By:	/s/ Dietrich Stephan	By:	/s/ Sam Backenroth
	Dietrich Stephan, Ph.D.		Sam Backenroth
	President and Chief Executive Officer (Principal Executive Officer)		Chief Financial Officer (Principal Financial and Accounting Officer)
	May 13, 2021		May 13, 2021

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

This certification accompanies the Report, is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.

EX-101.INS 5 nbse-20210331.xml XBRL INSTANCE DOCUMENT 0001173281 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2021-03-31 0001173281 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2021-03-31 0001173281 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2020-03-31 0001173281 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2020-03-31 0001173281 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2021-03-31 0001173281 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2021-03-31 0001173281 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-03-31 0001173281 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2020-03-31 0001173281 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2020-03-31 0001173281 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-03-31 0001173281 us-gaap:FairValueInputsLevel3Member 2021-03-31 0001173281 us-gaap:FairValueInputsLevel3Member 2020-09-30 0001173281 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001173281 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001173281 us-gaap:CommonStockMember 2019-10-01 2020-03-31 0001173281 us-gaap:RetainedEarningsMember 2021-03-31 0001173281 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001173281 us-gaap:RetainedEarningsMember 2020-12-31 0001173281 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001173281 us-gaap:RetainedEarningsMember 2020-09-30 0001173281 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001173281 us-gaap:RetainedEarningsMember 2020-03-31 0001173281 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001173281 us-gaap:RetainedEarningsMember 2019-12-31 0001173281 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001173281 us-gaap:RetainedEarningsMember 2019-09-30 0001173281 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001173281 us-gaap:SubsequentEventMember 2021-04-26 0001173281 srt:MinimumMember 2020-10-01 2021-03-31 0001173281 srt:MaximumMember 2020-10-01 2021-03-31 0001173281 us-gaap:OfficeEquipmentMember 2021-03-31 0001173281 nbse:LaboratoryEquipmentMember 2021-03-31 0001173281 us-gaap:OfficeEquipmentMember 2020-09-30 0001173281 nbse:LaboratoryEquipmentMember 2020-09-30 0001173281 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001173281 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001173281 us-gaap:RetainedEarningsMember 2019-10-01 2020-03-31 0001173281 2019-12-31 0001173281 2020-10-01 2020-12-31 0001173281 2019-10-01 2019-12-31 0001173281 nbse:JointVentureDepymedIncMember 2021-03-31 0001173281 nbse:JointVentureDepymedIncMember 2021-02-28 0001173281 us-gaap:CommonStockMember 2021-03-31 0001173281 us-gaap:CommonStockMember 2020-12-31 0001173281 us-gaap:CommonStockMember 2020-09-30 0001173281 us-gaap:CommonStockMember 2020-03-31 0001173281 us-gaap:CommonStockMember 2019-12-31 0001173281 us-gaap:CommonStockMember 2019-09-30 0001173281 nbse:StockIncentivePlan2019Member 2021-03-31 0001173281 nbse:StockIncentivePlan2016Member 2021-03-31 0001173281 2020-12-31 0001173281 2020-03-31 0001173281 2019-09-30 0001173281 us-gaap:WarrantMember 2020-10-01 2021-03-31 0001173281 us-gaap:EmployeeStockOptionMember 2020-10-01 2021-03-31 0001173281 us-gaap:WarrantMember 2019-10-01 2020-03-31 0001173281 us-gaap:RestrictedStockMember 2019-10-01 2020-03-31 0001173281 us-gaap:EmployeeStockOptionMember 2019-10-01 2020-03-31 0001173281 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001173281 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001173281 us-gaap:ResearchAndDevelopmentExpenseMember 2020-10-01 2021-03-31 0001173281 us-gaap:GeneralAndAdministrativeExpenseMember 2020-10-01 2021-03-31 0001173281 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001173281 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001173281 us-gaap:ResearchAndDevelopmentExpenseMember 2019-10-01 2020-03-31 0001173281 us-gaap:GeneralAndAdministrativeExpenseMember 2019-10-01 2020-03-31 0001173281 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001173281 2021-01-01 2021-03-31 0001173281 us-gaap:RetainedEarningsMember 2020-10-01 2021-03-31 0001173281 us-gaap:CommonStockMember 2020-10-01 2021-03-31 0001173281 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2021-03-31 0001173281 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001173281 2020-01-01 2020-03-31 0001173281 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2020-03-31 0001173281 nbse:WarrantsExpiringJuly2023Member 2021-03-31 0001173281 nbse:WarrantsExpiringDecember2021Member 2021-03-31 0001173281 nbse:WarrantsExpiringApril2022Member 2021-03-31 0001173281 us-gaap:SubsequentEventMember 2021-04-26 2021-04-26 0001173281 nbse:JointVentureDepymedIncMember 2020-10-01 2021-03-31 0001173281 2020-10-01 2020-10-31 0001173281 srt:MinimumMember 2021-05-01 0001173281 srt:MaximumMember 2021-05-01 0001173281 srt:MinimumMember 2020-12-01 2020-12-31 0001173281 srt:MaximumMember 2020-12-01 2020-12-31 0001173281 2020-10-31 0001173281 nbse:JointVentureDepymedIncMember 2021-01-01 2021-03-31 0001173281 nbse:JointVentureDepymedIncMember 2020-01-01 2020-03-31 0001173281 2021-02-28 0001173281 2019-10-01 2020-03-31 0001173281 2021-01-27 2021-01-27 0001173281 2020-09-30 0001173281 2021-03-31 0001173281 2021-05-12 0001173281 2020-10-01 2021-03-31 xbrli:pure iso4217:USD xbrli:shares nbse:director utr:sqft iso4217:USD xbrli:shares false --09-30 Q2 2021 2021-03-31 10-Q 0001173281 32716827 Yes false 333-88480 Non-accelerated Filer DE Yes NEUBASE THERAPEUTICS, INC. false true Common Stock, $0.0001 par value per share NASDAQ NBSE 250000 155865 79088 24716 258331 41313 217701 308635 162260 146375 196724 0 300000 -10000 -10000 -60000 -40000 14189 78000 71000 78000 71000 P10Y 300000 300000 <div> <div> 3.  Liquidity The Company has had no revenues from product sales and has incurred operating losses since inception. As of March 31, 2021, the Company had $24.2 million in cash and cash equivalents and during the six months ended March 31, 2021, incurred a loss from operations of $10.6 million and used $7.3 million of cash in operating activities. The Company has historically funded its operations primarily through the sale of common stock. On April 26, 2021, the Company closed on an underwritten public offering of you shares of its common stock (inclusive of 1,200,000 shares that were sold pursuant to the underwriters' full exercise of their option to purchase additional shares of the Company's common stock), at a price to the public of $5.00 per share. The Company expects that the net proceeds from the offering will be approximately $42.6 million, after deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company. The Company expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As a result, the Company will likely need to raise additional capital through one or more of the following: issuance of additional debt or equity, or complete a licensing transaction for one or more of the Company’s pipeline assets. Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these unaudited condensed consolidated financial statements were available to be issued. There can be no assurance that the Company will be successful in acquiring additional funding, that the Company's projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years. <div /></div> </div> 6 1 468807 880723 <div> <div> 4.  Other Prepaid Expenses and Other Current Assets The Company’s prepaid expenses and other current assets consisted of the following:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="top" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of March 31,  </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of September 30,  </td> </tr> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="top" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Prepaid research and development expense </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 29,422 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 205,641 </td> </tr> <tr> <td valign="top" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prepaid rent </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 301,481 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Other prepaid expenses and other current assets </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 105,491 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 88,999 </td> </tr> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    Total </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 436,394 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 294,640 </td> </tr> </table></div>   <div /></div> </div> 122919 138557 205641 29422 <div> <div> 2.  Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended September 30, 2020 included in the Company’s Annual Report on Form 10-K (the “Annual Report”) filed with the Securities and Exchange Commission (“SEC”) on December 23, 2020. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated during the consolidation process. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The accompanying unaudited condensed consolidated financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. In the opinion of management, the accompanying unaudited condensed consolidated financial statements for the periods presented reflect all adjustments, consisting of only normal, recurring adjustments, necessary to fairly state the Company’s financial position, results of operations and cash flows. The unaudited condensed consolidated financial statements for the interim periods are not necessarily indicative of results for the full year. The preparation of these unaudited condensed consolidated financial statements requires the Company to make estimates and judgments that affect the amounts reported in the financial statements and the accompanying notes. The Company’s actual results may differ from these estimates under different assumptions or conditions. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s unaudited condensed consolidated financial statements relate to the valuation of stock-based compensation, the fair value of warrant liabilities and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. The Company assesses and updates estimates each period to reflect current information, such as the economic considerations related to the impact that the novel coronavirus disease (“COVID-19”) could have on our significant accounting estimates (see Part II, Item 1A – Risk Factors—“Our operations may be adversely affected by the coronavirus outbreak, and we face risks that could impact our business” for further discussion of the effect of the COVID-19 pandemic on our operations). Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.   Fair Value Measurements Fair value measurements are based on the premise that fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the following three-tier fair value hierarchy has been used in determining the inputs used in measuring fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities on the reporting date. Level 2 – Pricing inputs are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Pricing inputs are generally unobservable and include situations where there is little, if any, market activity for the investment. The inputs into the determination of fair value require management’s judgment or estimation of assumptions that market participants would use in pricing the assets or liabilities. The fair values are therefore determined using factors that involve considerable judgment and interpretations, including but not limited to private and public comparables, third-party appraisals, discounted cash flow models, and fund manager estimates. Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Management’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange. Marketable Securities Marketable securities are classified as trading and are carried at fair value. The Company’s marketable securities consist of corporate bonds and highly liquid mutual funds and exchange-traded & closed-end funds which are valued at quoted market prices. The Company had no marketable securities as of March 31, 2021 and September 30, 2020. Net Loss Per Share Basic net loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the dilutive effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants and stock options that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive. The following potentially dilutive securities outstanding as of March 31, 2021 and 2020 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:21.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of March 31,  </td> </tr> <tr> <td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Common stock purchase options </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,552,884 </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,506,966 </td> </tr> <tr> <td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unvested restricted stock </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,125 </td> </tr> <tr> <td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Common stock purchase warrants </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 820,939 </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 715,939 </td> </tr> <tr> <td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,373,823 </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,226,030 </td> </tr> </table></div>   <a name="_Hlk63767048"></a>Recent Accounting Pronouncements In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes” (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments- Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). This guidance introduces a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. ASU 2016-13 also provides updated guidance regarding the impairment of available-for-sale debt securities and includes additional disclosure requirements. The new guidance is effective for public business entities that meet the definition of a Smaller Reporting Company as defined by the Securities and Exchange Commission for interim and annual periods beginning after December 15, 2022. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures. <div /></div> </div> 1200000 1200000 225000 820939 20.00 55.00 8.73 19.44 19.44 19.44 P1Y2M12D P1Y2M12D

<div> <div> 7. Accrued Expenses  and Other Current Liabilities The Company’s accrued expenses and other current liabilities consisted of the following:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:70.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of March 31,  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of September 30,  </td> </tr> <tr> <td valign="bottom" style="width:70.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:70.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued compensation and benefits </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 153,688 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 88,527 </td> </tr> <tr> <td valign="bottom" style="width:70.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued consulting settlement </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 250,000 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:70.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued professional fees </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 167,829 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 241,755 </td> </tr> <tr> <td valign="bottom" style="width:70.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued research and development </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 217,701 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 41,313 </td> </tr> <tr> <td valign="bottom" style="width:70.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued franchise tax </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 79,088 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 155,865 </td> </tr> <tr> <td valign="bottom" style="width:70.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued patent expenses </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 258,331 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 24,716 </td> </tr> <tr> <td valign="bottom" style="width:70.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Other accrued expenses </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,706 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,707 </td> </tr> <tr> <td valign="bottom" style="width:70.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    Total </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,130,343 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 555,883 </td> </tr> </table></div>   <div /></div> </div>

1505042

2175792

88527

153688

555883

1130343

241755

167829

158666

310084

74850935

77082072

2843636

1339410

2118693

942108

2843636

2067352

776284

1339410

954241

385169

2118693

1291159

827534

942108

448880

493228

7226030

6506966

3125

715939

7373823

6552884

820939

34444281

27473364

32808540

24940131

<div> <div> 1.  Organization and Description of Business NeuBase Therapeutics, Inc. and subsidiaries (the “Company” or “NeuBase”) is developing a modular peptide-nucleic acid (“PNA”) antisense oligo (“PATrOL™”) platform to address genetic diseases caused by mutant proteins, with a single, cohesive approach. The PATrOL™-enabled anti-gene therapies are designed to improve upon current genetic medicine strategies by combining the advantages of synthetic approaches with the precision of antisense technologies. NeuBase plans to use its platform to address diseases which have a genetic source, with an initial focus on Huntington’s Disease (“HD”) and Myotonic Dystrophy Type 1 (“DM1”), as well as other genetic disorders and cancer. NeuBase is a pre-clinical-stage biopharmaceutical company and continues to develop its clinical and regulatory strategy with its internal research and development team with a view toward prioritizing market introduction as quickly as possible. NeuBase’s lead programs are NT0100 and NT0200. The NT0100 program is a PATrOL™-enabled therapeutic program being developed to target the mutant expansion in the HD messenger ribonucleic acid (“RNA”). The NT0100 program includes several proprietary PNAs which have the potential to be highly selective for the mutant transcript vs. the wild-type transcribed allele and the expectation to be applicable for all HD patients as it directly targets the expansion itself, and has the potential to be delivered systemically. PATrOL™-enabled drugs also have the unique ability to open RNA secondary structures and bind to either the primary nucleotide sequences or the secondary and/or tertiary structures. NeuBase believes the NT0100 program addresses an unmet need for a disease which currently has no effective therapeutics that target the core etiology of the condition. NeuBase believes there is a large opportunity in the U.S. and European markets for drugs in this space. The NT0200 program is a PATrOL™-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease mRNA. The NT0200 program includes several proprietary PNAs which have the potential to be highly selective for the mutant transcript versus the wild-type transcribed allele and the expectation to be effective for nearly all DM1 patients as it directly targets the expansion itself. NeuBase believes the NT0200 program addresses an unmet need for a disease which currently has no effective therapeutics that target the core etiology of the condition. NeuBase believes there is also a large opportunity in the U.S. and European markets for drugs in this space. Acquisition On January 27, 2021, we entered into an Asset Purchase Agreement by and among us, NeuBase Corporation, our wholly owned subsidiary, and Vera Therapeutics, Inc. ("Vera") as amended by the Amendment to Asset Purchase Agreement, dated as of April 20, 2021, by and between the Company and Vera (collectively, the "APA"). Pursuant to the terms of the APA, we acquired infrastructure, materials, and intellectual property for peptide-nucleic acid ("PNA") scaffolds from Vera for total consideration of approximately $0.8 million in cash and 308,635 shares of Common Stock (of which 146,375 were to be issued to Vera and 162,260 will be held in escrow and released to Vera in accordance with the terms of an escrow agreement between NeuBase Corporation and Vera). The transaction closed on April 26, 2021, and we issued the shares to Vera on that date. <div /></div> </div>

<div> <div> Basis of Presentation The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended September 30, 2020 included in the Company’s Annual Report on Form 10-K (the “Annual Report”) filed with the Securities and Exchange Commission (“SEC”) on December 23, 2020. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated during the consolidation process. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The accompanying unaudited condensed consolidated financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. In the opinion of management, the accompanying unaudited condensed consolidated financial statements for the periods presented reflect all adjustments, consisting of only normal, recurring adjustments, necessary to fairly state the Company’s financial position, results of operations and cash flows. The unaudited condensed consolidated financial statements for the interim periods are not necessarily indicative of results for the full year. The preparation of these unaudited condensed consolidated financial statements requires the Company to make estimates and judgments that affect the amounts reported in the financial statements and the accompanying notes. The Company’s actual results may differ from these estimates under different assumptions or conditions. <div /></div> </div>

234104

10313966

5771948

31992283

24246752

24200000

-4542018

-7745531

820939

695312

20627

105000

<div> <div> 11. Commitments and Contingencies Operating Leases In October 2020, the Company entered into a ten-year lease agreement with annual escalating rental payments for office and laboratory space in Pittsburgh, Pennsylvania. The leased premises will serve as the Company’s headquarters upon the commencement of the lease. The initial term of the lease commences upon the landlord’s delivery of the leased premises in tenant improvement readiness condition, which occurred on May 1, 2021. The initial term of the lease will extend approximately ten years from delivery of the leased premises to the Company, unless earlier terminated in accordance with the lease. The Company has the right to extend the term of the lease for an additional five-year term. Under the lease, the Company will lease approximately 14,189 square feet of the property. Pursuant to amendment 1 to the lease agreement during December 2020, and amendment 2 to the lease agreement in April 2021, the Company will pay an escalating base rent over the life of the lease of approximately $71,000 to $78,000 per month, and the Company will pay its pro rata portion of property expenses and operating expenses for the property. The Company will measure and recognize the right-of-use (“ROU”) asset and operating lease liability upon lease commencement. During the six months ended March 31, 2021, the Company prepaid rent of $0.3 million and paid a security deposit of $0.3 million for this lease agreement. The Company currently leases its existing office and operating space under operating leases with original terms of less than 12 months and which expire at various dates through November 2021; therefore, the Company’s operating leases are not recognized as ROU assets on the unaudited condensed consolidated balance sheet as of March 31, 2021. Rent expense under the Company’s operating leases totaled approximately $0.03 million and $0.02 million for the three months ended March 31, 2021 and 2020, respectively. Rent expense under the Company's operating leases totaled approximately $0.06 million and $0.04 million for the six months ended March 31, 2021 and 2020, respectively. The Company continues to operate under its current operating lease in Pittsburgh on a month-to-month basis and will continue to operate under the lease until the Company moves into its new headquarters and laboratory space, which is expected to occur in June 2021. All terms and conditions remain the same from the current lease. In November 2020, the Company extended the term of its rental of office space in New York until November 2021. Litigation The Company has become involved in certain legal proceedings and claims which arise in the normal course of business. If an unfavorable ruling were to occur, there exists the possibility of a material adverse impact on the Company’s results of operations, prospects, cash flows, financial position and brand. On February 14, 2018, plaintiff Jeevesh Khanna, commenced an action in the Southern District of New York, against Ohr and several current and former officers and directors, alleging that they violated federal securities laws between June 24, 2014 and January 4, 2018. On August 7, 2018, the lead plaintiffs, now George Lehman and Insured Benefit Plans, Inc., filed an amended complaint, stating the class period to be April 8, 2014 through January 4, 2018. The plaintiffs did not quantify any alleged damages in their complaint but, in addition to attorneys’ fees and costs, they seek to maintain the action as a class action and to recover damages on behalf of themselves and other persons who purchased or otherwise acquired Ohr common stock during the putative class period and purportedly suffered financial harm as a result. We and the individuals dispute these claims and intend to defend the matter vigorously. On September 17, 2018, Ohr filed a motion to dismiss the complaint. On September 20, 2019, the district court entered an order granting the defendants’ motion to dismiss. On October 23, 2019, the plaintiffs filed a notice of appeal of that order dismissing the action and other related orders by the district court. After full briefing and oral argument, on October 9, 2020, the U.S. Court of Appeals for the Second Circuit issued a summary order affirming the district court’s order granting the motion to dismiss and remanding the action to the district court to make a determination on the record related to plaintiffs’ request for leave to file an amended complaint. On October 16, 2020, the district court requested the parties’ positions as to how they proposed to proceed in light of the Second Circuit’s decision. After letter briefing on this issue and plaintiffs’ alternative request for leave to file a second amended complaint, on November 16, 2020, the district court denied plaintiffs’ request to amend and dismissed with prejudice plaintiffs’ claims. On December 16, 2020, plaintiffs filed a notice of appeal of that order denying plaintiffs leave to amend, and the plaintiffs filed their appellate brief with respect to such matters with the Court on March 31, 2021. This litigation could result in substantial costs and a diversion of management’s resources and attention, which could harm the Company’s business and the value of the Company's common stock. On May 3, 2018, plaintiff Adele J. Barke, derivatively on behalf of Ohr, commenced an action against certain former directors of Ohr, including Michael Ferguson, Orin Hirschman, Thomas M. Riedhammer, June Almenoff and Jason S. Slakter in the Supreme Court, State of New York, alleging that the action was brought in the right and for the benefit of Ohr seeking to remedy their “breach of fiduciary duties, corporate waste and unjust enrichment that occurred between June 24, 2014 and the present.” It does not quantify any alleged damages. We and the individuals dispute these claims and intend to defend the matter vigorously. Such litigation has been stayed pursuant to a stipulation by the parties, which has been so ordered by the court, pending a decision in the Southern District case on the motion to dismiss, but that status could change. This litigation could result in substantial costs and a diversion of management’s resources and attention, which could harm our business and the value of our common stock. On March 20, 2019, a putative class action lawsuit was filed in the United States District Court for District of Delaware naming as defendants Ohr and its board of directors, Legacy NeuBase and Ohr Acquisition Corp., captioned Wheby v. Ohr Pharmaceutical, Inc., et al., Case No. 1:19-cv-00541-UNA (the “Wheby Action”). The plaintiffs in the Wheby Action allege that the preliminary joint proxy/prospectus statement filed by Ohr with the SEC on March 8, 2019 contained false and misleading statements and omitted material information in violation of Section 14(a) of the Exchange Act and SEC Rule 14a-9 promulgated thereunder, and further that the individual defendants are liable for those alleged misstatements and omissions under Section 20(a) of the Exchange Act. The complaint in the Wheby Action has not been served on, nor was service waived by, any of the named defendants in that action. The action seeks, among other things, to rescind the Merger or an award of damages, and an award of attorneys’ and experts’ fees and expenses. The defendants dispute the claims raised in the Wheby Action. Management believes that the likelihood of an adverse decision from the sole remaining action is unlikely; however, the litigation could result in substantial costs and a diversion of management’s resources and attention, which could harm our business and the value of our common stock. <div /></div> </div>

147041

1294956

0.0001

250000000

23154084

23180024

17077873

17080625

23154084

23177591

23180024

2315

2317

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="top" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of March 31,  </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of September 30,  </td> </tr> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="top" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Prepaid research and development expense </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 29,422 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 205,641 </td> </tr> <tr> <td valign="top" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prepaid rent </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 301,481 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Other prepaid expenses and other current assets </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 105,491 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 88,999 </td> </tr> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    Total </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 436,394 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 294,640 </td> </tr> </table></div>   <div /></div> </div>

50000

30000

150000

80000

199500

151418

<div> <div> 10.  Stock-Based Compensation As of March 31, 2021, an aggregate of 4,709,277 shares of common stock were authorized under the Company’s 2019 Stock Incentive Plan (the “2019 Plan”), subject to an “evergreen” provision that will automatically increase the maximum number of shares of common stock that may be issued under the term of the 2019 Plan. As of March 31, 2021,  1,294,956 common shares were available for future grants under the 2019 Plan. As of March 31, 2021, 291,667 shares of common stock were authorized under the Company’s 2016 Consolidated Stock Incentive Plan (the “2016 Plan”) and 147,041 common shares were available for future grants under the 2016 Plan. The Company recorded stock-based compensation expense in the following expense categories of its unaudited condensed consolidated statements of operations for the three and six months ended March 31, 2021 and 2020:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:50.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="top" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:50.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="top" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:22.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months ended March 31, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:22.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months ended March 31, </td> </tr> <tr> <td valign="bottom" style="width:50.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="top" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:50.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> General and administrative </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 448,880 </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 954,241 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,291,159 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,067,352 </td> </tr> <tr> <td valign="bottom" style="width:50.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 493,228 </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 385,169 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 827,534 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 776,284 </td> </tr> <tr> <td valign="bottom" style="width:50.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 942,108 </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,339,410 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,118,693 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,843,636 </td> </tr> </table></div>   Stock Options Below is a table summarizing the options issued and outstanding as of and for the six months ended March 31, 2021:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:42.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> </tr> <tr> <td valign="bottom" style="width:42.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> </tr> <tr> <td valign="bottom" style="width:42.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual Life </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic </td> </tr> <tr> <td valign="bottom" style="width:42.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Stock Options </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in years) </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> </tr> <tr> <td valign="bottom" style="width:42.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at September 30, 2020 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,190,790 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.76 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:42.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 534,340 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7.59 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:42.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (21,576) </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.21 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (150,670) </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5.68 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at March 31, 2021 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,552,884 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.08 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.1 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 29,219,357 </td> </tr> <tr> <td valign="bottom" style="width:42.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Exercisable as of March 31, 2021 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,575,375 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.65 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7.7 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 26,884,291 </td> </tr> </table></div>   As of March 31, 2021, unrecognized compensation costs associated with the stock options of $4.8 million will be recognized over an estimated weighted-average amortization period of 1.3 years. The weighted average grant date fair value of options granted during the six months ended March 31, 2021 and 2020 was $5.32 and $4.78, respectively. Key assumptions used to estimate the fair value of the stock options granted during the six months ended March 31, 2021 and 2020 included:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:72.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:25.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months ended March 31,  </td> </tr> <tr> <td valign="bottom" style="width:72.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:72.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term of options (years) </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  5.5 - 7.0  </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7.0 </td> </tr> <tr> <td valign="bottom" style="width:72.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected common stock price volatility </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  83% - 83.3% </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  78% - 83.5% </td> </tr> <tr> <td valign="bottom" style="width:72.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  0.6% - 1.3% </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  0.9% - 1.8% </td> </tr> <tr> <td valign="bottom" style="width:72.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected dividend yield </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> </table></div>   During the six months ended March 31, 2021, the Company granted a stock option to purchase 225,000 shares to a consultant in recognition of future service to the Company as an employee. The exercisability and vesting of the stock options are subject to the consultant's effective date of employment with the Company, which has not yet occurred as of March 31, 2021, and as a result, the grant-date of such option has not occurred under GAAP. Therefore, the number and fair value of the shares subject to this option are not reflected in the table summarizing the options issued and outstanding as of and for the six months ended March 31, 2021 and did not have impact on unrecognized compensation costs or the estimated weighted-average amortization period above as of March 31, 2021. Restricted Stock A summary of the changes in the unvested restricted stock during the six months ended March 31, 2021 is as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:63.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> </tr> <tr> <td valign="bottom" style="width:63.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> </tr> <tr> <td valign="bottom" style="width:63.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   Grant Date </td> </tr> <tr> <td valign="bottom" style="width:63.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:19.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unvested Restricted </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">  Fair Value </td> </tr> <tr> <td valign="bottom" style="width:63.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:19.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">  Stock </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> </tr> <tr> <td valign="bottom" style="width:63.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested as of September 30, 2020 </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:63.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,364 </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 9.17 </td> </tr> <tr> <td valign="bottom" style="width:63.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Vested </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (4,364) </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 9.17 </td> </tr> <tr> <td valign="bottom" style="width:63.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unvested as of March 31, 2021 </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> </table></div>   <div /></div> </div>

-0.52

-0.26

-0.41

-0.24

<div> <div> Net Loss Per Share Basic net loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the dilutive effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants and stock options that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive. The following potentially dilutive securities outstanding as of March 31, 2021 and 2020 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:21.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of March 31,  </td> </tr> <tr> <td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Common stock purchase options </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,552,884 </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,506,966 </td> </tr> <tr> <td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unvested restricted stock </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,125 </td> </tr> <tr> <td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Common stock purchase warrants </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 820,939 </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 715,939 </td> </tr> <tr> <td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,373,823 </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,226,030 </td> </tr> </table></div>   <div /></div> </div>

P1Y3M18D

4800000

0.1300

300000

600000

<div> <div> 6.  Investment The Company owns common and preferred shares of DepYmed, Inc. (“DepYmed”), which in aggregate represents approximately 13% ownership of DepYmed and includes recently acquired DepYmed Series A-4 preferred shares with a fair value of approximately $0.3 million that were issued to the Company in February 2021 in exchange for the Company's sale of certain intellectual property. In addition, the Company is entitled to hold one of the six seats on DepYmed’s board of directors. The Company accounts for its investment in DepYmed common shares using the equity method of accounting and records its proportionate share of DepYmed’s net income and losses in the accompanying unaudited condensed consolidated statements of operations. Equity in losses for the three months ended March 31, 2021 and 2020 were approximately $0.04 million and $0.01 million, respectively.  Equity in losses for the six months ended March 31, 2021 and 2020 were approximately $0.06 million and $0.01 million, respectively. The Company accounts for its investment in preferred shares of DepYmed at cost, less any impairment, as the Company determined the preferred stock did not have a readily determinable fair value. As of both March 31, 2021 and September 30, 2020, the carrying amount of the Company’s aggregate investment in DepYmed was $0.6 million and $0.3 million, respectively. <div /></div> </div>

624190

-69944

-720709

-90597

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:63.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:34.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of March 31,  </td> </tr> <tr> <td valign="bottom" style="width:63.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:63.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Remaining contractual term (years) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  0.7 - 1.0 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  1.7 - 2.0 </td> </tr> <tr> <td valign="bottom" style="width:63.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Common stock price volatility </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  69.5% - 71.4%  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  89.6% - 92.5%  </td> </tr> <tr> <td valign="bottom" style="width:63.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.07% </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.23% </td> </tr> <tr> <td valign="bottom" style="width:63.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected dividend yield </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:63.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> 8. Fair Value The following tables present the Company’s fair value hierarchy for its warrant liabilities measured at fair value on a recurring basis at March 31, 2021 and September 30, 2020:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:53.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="11" valign="bottom" style="width:44.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair Value Measurements  </td> </tr> <tr> <td valign="bottom" style="width:53.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:44.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> as of March 31, 2021 </td> </tr> <tr> <td valign="bottom" style="width:53.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> </tr> <tr> <td valign="bottom" style="width:53.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Liabilities </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:53.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Warrant liabilities </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 229,442 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 229,442 </td> </tr> <tr> <td valign="bottom" style="width:53.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:44.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Fair Value Measurements  </td> </tr> <tr> <td valign="bottom" style="width:53.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:44.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> as of September 30, 2020 </td> </tr> <tr> <td valign="bottom" style="width:53.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (Level 3) </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  Total   </td> </tr> <tr> <td valign="bottom" style="width:53.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Liabilities </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Warrant liabilities </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 950,151 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 950,151 </td> </tr> </table></div>   The fair value of the warrant liabilities were determined using the Black-Scholes option pricing model. The following assumptions were used in determining the fair value of the warrant liabilities :   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:63.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:34.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of March 31,  </td> </tr> <tr> <td valign="bottom" style="width:63.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:63.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Remaining contractual term (years) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  0.7 - 1.0 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  1.7 - 2.0 </td> </tr> <tr> <td valign="bottom" style="width:63.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Common stock price volatility </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  69.5% - 71.4%  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  89.6% - 92.5%  </td> </tr> <tr> <td valign="bottom" style="width:63.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.07% </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.23% </td> </tr> <tr> <td valign="bottom" style="width:63.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected dividend yield </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:63.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   The Company was historically a private company and lacked company-specific historical and implied volatility information, therefore the Company estimated its expected stock volatility based on the historical volatility of a set of publicly traded peer companies. During the three and six months ended March 31, 2021, the Company utilized its historical volatility in the valuation of warrant liabilities as it had sufficient trading history. The change in fair value of the warrant liabilities for the three and six months ended March 31,2021 and 2020 is as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:84.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Fair value as of September 30, 2020 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 950,151 </td> </tr> <tr> <td valign="bottom" style="width:84.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Change in fair value </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (630,112) </td> </tr> <tr> <td valign="bottom" style="width:84.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Fair value as of December 31, 2020 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 320,039 </td> </tr> <tr> <td valign="bottom" style="width:84.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Change in fair value </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (90,597) </td> </tr> <tr> <td valign="bottom" style="width:84.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Fair value as of March 31, 2021 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 229,442 </td> </tr> <tr> <td valign="bottom" style="width:84.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Fair value as of September 30, 2019 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 496,343 </td> </tr> <tr> <td valign="bottom" style="width:84.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Change in fair value </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 694,134 </td> </tr> <tr> <td valign="bottom" style="width:84.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Fair value as of December 31, 2019 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,190,477 </td> </tr> <tr> <td valign="bottom" style="width:84.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Change in fair value </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (69,944) </td> </tr> <tr> <td valign="bottom" style="width:84.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Fair value as of March 31, 2020 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,120,533 </td> </tr> </table></div>   As of March 31, 2021 and September 30, 2020, the recorded values of cash and cash equivalents, accounts payable and the insurance note payable approximate fair value due to the short-term nature of these instruments. <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:53.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="11" valign="bottom" style="width:44.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair Value Measurements  </td> </tr> <tr> <td valign="bottom" style="width:53.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:44.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> as of March 31, 2021 </td> </tr> <tr> <td valign="bottom" style="width:53.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> </tr> <tr> <td valign="bottom" style="width:53.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Liabilities </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:53.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Warrant liabilities </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 229,442 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 229,442 </td> </tr> <tr> <td valign="bottom" style="width:53.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:44.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Fair Value Measurements  </td> </tr> <tr> <td valign="bottom" style="width:53.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:44.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> as of September 30, 2020 </td> </tr> <tr> <td valign="bottom" style="width:53.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (Level 3) </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  Total   </td> </tr> <tr> <td valign="bottom" style="width:53.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Liabilities </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:53.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Warrant liabilities </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 950,151 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 950,151 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:84.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Fair value as of September 30, 2020 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 950,151 </td> </tr> <tr> <td valign="bottom" style="width:84.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Change in fair value </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (630,112) </td> </tr> <tr> <td valign="bottom" style="width:84.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Fair value as of December 31, 2020 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 320,039 </td> </tr> <tr> <td valign="bottom" style="width:84.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Change in fair value </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (90,597) </td> </tr> <tr> <td valign="bottom" style="width:84.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Fair value as of March 31, 2021 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 229,442 </td> </tr> <tr> <td valign="bottom" style="width:84.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Fair value as of September 30, 2019 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 496,343 </td> </tr> <tr> <td valign="bottom" style="width:84.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Change in fair value </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 694,134 </td> </tr> <tr> <td valign="bottom" style="width:84.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Fair value as of December 31, 2019 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,190,477 </td> </tr> <tr> <td valign="bottom" style="width:84.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Change in fair value </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (69,944) </td> </tr> <tr> <td valign="bottom" style="width:84.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Fair value as of March 31, 2020 </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,120,533 </td> </tr> </table></div>   <div /></div> </div>

694134

-69944

-630112

-90597

496343

1190477

1120533

950151

320039

229442

<div> <div>   Fair Value Measurements Fair value measurements are based on the premise that fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the following three-tier fair value hierarchy has been used in determining the inputs used in measuring fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities on the reporting date. Level 2 – Pricing inputs are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Pricing inputs are generally unobservable and include situations where there is little, if any, market activity for the investment. The inputs into the determination of fair value require management’s judgment or estimation of assumptions that market participants would use in pricing the assets or liabilities. The fair values are therefore determined using factors that involve considerable judgment and interpretations, including but not limited to private and public comparables, third-party appraisals, discounted cash flow models, and fund manager estimates. Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Management’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange. <div /></div> </div>

316724

-3230

5293701

2739021

5363110

2721640

-117351

-92842

-61539

-36127

186911

436646

340288

574460

-214698

-122878

-96833

-96834

-253565

1653

342

16197

6460

1668

10400

9466

true

P5Y

P10Y

3149633

3535577

34444281

27473364

323557

578742

-15006

-122919

-26111

-161916

-417896

-4257183

-7301524

-7300000

-8883820

-4378270

-9588000

-5521569

<div> <div> <a name="_Hlk63767048"></a>Recent Accounting Pronouncements In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes” (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments- Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). This guidance introduces a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. ASU 2016-13 also provides updated guidance regarding the impairment of available-for-sale debt securities and includes additional disclosure requirements. The new guidance is effective for public business entities that meet the definition of a Smaller Reporting Company as defined by the Securities and Exchange Commission for interim and annual periods beginning after December 15, 2022. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures. <div /></div> </div>

138557

8137396

4355030

10557163

5895769

-8137396

-4355030

-10557163

-5895769

40000

20000

60000

30000

3707

3706

-3230

316724

950151

229442

-746424

-23240

969163

374200

88999

105491

44990079

800000

161916

402890

0.0001

10000000

294640

436394

145250

48416

521617

256985

301481

42600000

44975073

112446

<div> <div> 5.  Equipment The Company’s equipment consisted of the following:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="top" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of March 31,  </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of September 30,  </td> </tr> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="top" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Laboratory equipment </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,825,393 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,319,123 </td> </tr> <tr> <td valign="top" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Office equipment </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 137,201 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,477 </td> </tr> <tr> <td valign="top" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">     Total </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,962,594 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,325,600 </td> </tr> <tr> <td valign="top" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accumulated depreciation </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (310,084) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (158,666) </td> </tr> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">     Property, plant and equipment, net </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,652,510 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,166,934 </td> </tr> </table></div>   Depreciation expense for the three months ended March 31, 2021 and 2020 was approximately $0.08 million and $0.03, respectively. Depreciation expense for the six months ended March 31, 2021 and 2020 was approximately $0.15 million and $0.05, respectively. <div /></div> </div>

1325600

1319123

6477

1962594

1825393

137201

1166934

1652510

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="top" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of March 31,  </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of September 30,  </td> </tr> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="top" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Laboratory equipment </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,825,393 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,319,123 </td> </tr> <tr> <td valign="top" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Office equipment </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 137,201 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,477 </td> </tr> <tr> <td valign="top" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">     Total </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,962,594 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,325,600 </td> </tr> <tr> <td valign="top" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accumulated depreciation </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (310,084) </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (158,666) </td> </tr> <tr> <td valign="bottom" style="width:69.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">     Property, plant and equipment, net </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,652,510 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,166,934 </td> </tr> </table></div>   <div /></div> </div>

2843695

1616009

5194053

3174129

-43558602

-53146602

<div> <div> The Company recorded stock-based compensation expense in the following expense categories of its unaudited condensed consolidated statements of operations for the three and six months ended March 31, 2021 and 2020:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:50.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="top" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:50.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="top" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:22.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months ended March 31, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:22.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months ended March 31, </td> </tr> <tr> <td valign="bottom" style="width:50.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="top" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:50.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> General and administrative </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 448,880 </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 954,241 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,291,159 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,067,352 </td> </tr> <tr> <td valign="bottom" style="width:50.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 493,228 </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 385,169 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 827,534 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 776,284 </td> </tr> <tr> <td valign="bottom" style="width:50.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 942,108 </td> <td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,339,410 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,118,693 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,843,636 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> Below is a table summarizing the options issued and outstanding as of and for the six months ended March 31, 2021:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:42.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> </tr> <tr> <td valign="bottom" style="width:42.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> </tr> <tr> <td valign="bottom" style="width:42.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual Life </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic </td> </tr> <tr> <td valign="bottom" style="width:42.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Stock Options </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in years) </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> </tr> <tr> <td valign="bottom" style="width:42.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at September 30, 2020 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,190,790 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.76 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:42.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 534,340 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7.59 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:42.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (21,576) </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.21 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (150,670) </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5.68 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at March 31, 2021 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,552,884 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.08 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.1 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 29,219,357 </td> </tr> <tr> <td valign="bottom" style="width:42.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Exercisable as of March 31, 2021 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,575,375 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.65 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7.7 </td> <td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 26,884,291 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> A summary of the changes in the unvested restricted stock during the six months ended March 31, 2021 is as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:63.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> </tr> <tr> <td valign="bottom" style="width:63.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> </tr> <tr> <td valign="bottom" style="width:63.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   Grant Date </td> </tr> <tr> <td valign="bottom" style="width:63.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:19.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unvested Restricted </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">  Fair Value </td> </tr> <tr> <td valign="bottom" style="width:63.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:19.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">  Stock </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> </tr> <tr> <td valign="bottom" style="width:63.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested as of September 30, 2020 </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:63.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,364 </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 9.17 </td> </tr> <tr> <td valign="bottom" style="width:63.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Vested </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (4,364) </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 9.17 </td> </tr> <tr> <td valign="bottom" style="width:63.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unvested as of March 31, 2021 </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> </table></div>   <div /></div> </div>

<div> <div> Key assumptions used to estimate the fair value of the stock options granted during the six months ended March 31, 2021 and 2020 included:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:72.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:25.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months ended March 31,  </td> </tr> <tr> <td valign="bottom" style="width:72.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:72.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term of options (years) </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  5.5 - 7.0  </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7.0 </td> </tr> <tr> <td valign="bottom" style="width:72.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected common stock price volatility </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  83% - 83.3% </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  78% - 83.5% </td> </tr> <tr> <td valign="bottom" style="width:72.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  0.6% - 1.3% </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  0.9% - 1.8% </td> </tr> <tr> <td valign="bottom" style="width:72.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected dividend yield </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> </table></div>   <div /></div> </div>

<div> <div>     <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrants </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Expiration date </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise Price </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Outstanding </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> December 13, 2021 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 55.00 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,627 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> April 10, 2022 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 20.00 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 695,312 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> July 6, 2023 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.73 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 105,000 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 820,939 </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:52.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:52.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> </tr> <tr> <td valign="bottom" style="width:52.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> </tr> <tr> <td valign="bottom" style="width:52.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> </tr> <tr> <td valign="bottom" style="width:52.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual Life </td> </tr> <tr> <td valign="bottom" style="width:52.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in years) </td> </tr> <tr> <td valign="bottom" style="width:52.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding as of September 30, 2020 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 820,939 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 19.44 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:52.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Outstanding as of March 31, 2021 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 820,939 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 19.44 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.2 </td> </tr> <tr> <td valign="bottom" style="width:52.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercisable as of March 31, 2021 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 820,939 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 19.44 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.2 </td> </tr> </table></div>   <div /></div> </div>

253565

2843636

2118693

4364

4.78

5.32

4364

P7Y

P5Y6M

0.835

0.833

0.78

0.830

0.018

0.013

0.009

0.006

291667

4709277

26884291

4575375

1.65

P7Y8M12D

150670

534340

9.17

29219357

6190790

6552884

2.76

3.08

P8Y1M6D

9.17

5.21

5.68

7.59

5.00

10029384

36201758

1708

-26174082

7028060

37705984

1708

-30679632

3989200

39045394

1708

-35057902

31294648

74850935

2315

-43558602

28517248

76139964

2317

-47625033

23937787

77082072

2317

-53146602

<div> <div> 9.  Stockholders’ Equity Warrants Below is a summary of the Company’s issued and outstanding warrants as of March 31, 2021:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrants </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Expiration date </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise Price </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Outstanding </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> December 13, 2021 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 55.00 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,627 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> April 10, 2022 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 20.00 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 695,312 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> July 6, 2023 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.73 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 105,000 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 820,939 </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:52.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:52.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> </tr> <tr> <td valign="bottom" style="width:52.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> </tr> <tr> <td valign="bottom" style="width:52.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> </tr> <tr> <td valign="bottom" style="width:52.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual Life </td> </tr> <tr> <td valign="bottom" style="width:52.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in years) </td> </tr> <tr> <td valign="bottom" style="width:52.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding as of September 30, 2020 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 820,939 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 19.44 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:52.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Outstanding as of March 31, 2021 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 820,939 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 19.44 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.2 </td> </tr> <tr> <td valign="bottom" style="width:52.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercisable as of March 31, 2021 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 820,939 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 19.44 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.2 </td> </tr> </table></div>   <div /></div> </div>

2752

4364

2433

9200000

21576

2752

112446

112444

<div> <div>   12. Subsequent Events On April 21, 2021, the Company entered into a second amendment (the "Second Amendment") to the Lease Agreement (as amended, the "Lease") with 350 Technology Drive Partners, LLC (the "Landlord") for office and laboratory space (the "Leased Premises") located at 350 Technology Drive, Pittsburgh, Pennsylvania. Pursuant to the Second Amendment, the parties amended the Lease to provide that the Lease will commence on May 1, 2021. On such date, the Company is obligated to begin making rental payments, provided that the Company may be entitled to a rental credit for certain periods based on the date the Landlord delivers possession of the office space and biology lab within the Leased Premises to the Company and the date the Landlord substantially completes tenant improvements. In addition, pursuant to the Second Amendment and as a result of approved change orders, the Company will pay an escalating base rent over the life of the Lease of approximately $71,000 to $78,000 per month. Refer to the discussion in Note 10. On April 26, 2021, the Company closed on an underwritten public offering of 9,200,000 shares of its common stock (inclusive of 1,200,000 shares that were sold pursuant to the underwriters' full exercise of their option to purchase additional shares of the Company's common stock), at a price to the public of $5.00 per share. Refer to the discussion in Note 3. On April 26, 2021, the Company closed the Vera transaction. Refer to the discussion in Note 1. [Open] <div /></div> </div>

<div> <div> Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s unaudited condensed consolidated financial statements relate to the valuation of stock-based compensation, the fair value of warrant liabilities and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. The Company assesses and updates estimates each period to reflect current information, such as the economic considerations related to the impact that the novel coronavirus disease (“COVID-19”) could have on our significant accounting estimates (see Part II, Item 1A – Risk Factors—“Our operations may be adversely affected by the coronavirus outbreak, and we face risks that could impact our business” for further discussion of the effect of the COVID-19 pandemic on our operations). Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.   <div /></div> </div>

950151

229442

0.23

92.5

89.6

0.07

71.4

69.5

P2Y

P1Y8M11D

P1Y

P0Y8M11D

17073765

17075875

23176877

23179646

EX-101.SCH 6 nbse-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Other Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Organization and Description of Business - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Significant Accounting Policies - Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Significant Accounting Policies - Potentially dilutive securities outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Investment (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Fair Value - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Stockholders' Equity - Warrants issued and outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Stock-Based Compensation - Key Assumptions Estimate Fair Value Of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 41003 - Disclosure - Stock-Based Compensation - Restricted Stock (Details) link:presentationLink link:calculationLink link:definitionLink 41004 - Disclosure - Stock-Based Compensation - Stock-based compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 41005 - Disclosure - Stock-Based Compensation - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Liquidity link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Other Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Equipment link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Investment link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Fair Value link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Other Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Fair Value (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Equipment - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Stock-Based Compensation - Stock options (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 nbse-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 nbse-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 nbse-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information Document Type Document Period End Date Entity File Number Entity Registrant Name Entity Incorporation, State Code Title of 12(b) Security Trading Symbol Security Exchange Name Entity's Reporting Status Current Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Condensed Consolidated Balance Sheets ASSETS CURRENT ASSETS Cash Cash and cash equivalents, end of period Cash and cash equivalents, beginning of period Cash and cash equivalents Prepaid Insurance Prepaid insurance Prepaid Expense and Other Assets, Current Total Other prepaid expenses and current assets Assets, Current Total Current Assets EQUIPMENT, net Property, Plant and Equipment, Net OTHER ASSETS Long-term Investments Investment Prepaid Expense, Noncurrent Long-term prepaid insurance Security Deposit Security deposit It represents value of other non current assets Other Assets Total Total Other Assets Assets. TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses and other current liabilities Total Other Liabilities, Current Warrant liabilities Notes payable Insurance note payable Liabilities, Current Total Current Liabilities Liabilities Total Liabilities .Commitments and Contingencies COMMITMENTS AND CONTINGENCIES Preferred stock, Series B, $0.0001 par value; 6,000,000 shares authorized, 0 shares issued and outstanding as of June 30, 2019 and September 30, 2018 Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2020 and September 30, 2020 Common stock, $0.0001 par value; 180,000,000 shares authorized, 2,829,248 shares issued and outstanding as of June 30, 2019 and September 30, 2018 Common stock, $0.0001 par value; 250,000,000 shares authorized; 23,177,591 and 23,154,084 shares issued and outstanding as of December 31,2020 and September 30, 2020, respectively Additional paid-in capital. Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Balance, ending Balance, beginning Total stockholders' equity Liabilities and Equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Preferred stock, par value (in dollars per share) Preferred stock, authorized Preferred stock, issued Preferred stock, outstanding Common stock, par value (in dollars per share) Common stock, authorized Common stock, issued Common stock, outstanding Balance, ending, shares Balance, beginning, shares Condensed Consolidated Statements of Operations OPERATING EXPENSES OPERATING EXPENSES General and administrative General and administrative Research and development Research and development Operating Expenses. TOTAL OPERATING EXPENSES Operating Income (Loss) Loss from operations LOSS FROM OPERATIONS Nonoperating Income (Expense) [Abstract] OTHER INCOME (EXPENSE) Interest expense Interest expense Interest income Fair Value Adjustment of Warrants Change in fair value of warrant liabilities Change in fair value of warrant liabilities Income (Loss) from Equity Method Investments Equity in losses on equity method investment Equity in losses on equity method investment Other Income Other income (expense) Other Nonoperating Income (Expense) Total other income (expenses), net Net loss Net loss NET LOSS BASIC AND DILUTED LOSS PER SHARE (in dollars per share) BASIC AND DILUTED LOSS PER SHARE (in dollars per share) WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: WEIGHTED AVERAGE SHARES OUTSTANDING: BASIC AND DILUTED (in shares) BASIC AND DILUTED Condensed Consolidated Statements of Stockholders' Equity Statement [Table] Statement [Line Items] APIC, Share-based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense Stock Issued During Period, Value, New Issues Issuance of common stock, net of issuance costs Stock Issued During Period, Shares, New Issues Common stock issued for cash (in shares) Issuance of common stock, net of issuance costs (in shares) Stock Issued During Period, Value, Issued for Services Issuance of restricted stock for services Issuance restricted stock for services Issuance of restricted stock for services (in shares) Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised Exercise of stock options (in shares) Condensed Consolidated Statements of Cash Flows OPERATING ACTIVITIES Cash flows from operating activities: Adjustments to reconcile net loss to net cash used by operating activities Adjustments to reconcile net loss to net cash used in operating activities Stock option and warrant expense Stock-based compensation Depreciation and amortization Depreciation and amortization Marketable Securities, Gain (Loss) Loss on marketable security Gain (Loss) on Disposition of Property Plant Equipment Loss on disposal of fixed asset Gain (Loss) on Disposition of Intangible Assets Gain on sale of intellectual property Changes in operating assets and liabilities Changes in operating assets and liabilities Increase (Decrease) in Prepaid Expense and Other Assets Prepaid insurance, other expenses and current assets Increase (Decrease) in Prepaid Insurance Long-term prepaid insurance Increase (Decrease) in Security Deposits Security Deposit Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued expenses and other current liabilities Net Cash Provided by (Used in) Operating Activities Cash in operating activities Net cash used in operating activities INVESTING ACTIVITIES Cash flows from investing activities Payments to Acquire Property, Plant, and Equipment Purchase of laboratory and office equipment Payments to Acquire Marketable Securities Purchase of marketable securities Proceeds from Sale and Maturity of Marketable Securities Sale of marketable securities Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities FINANCING ACTIVITIES Cash flows from financing activities It represents the total of the cash outflow during the period which has been paid to financing insurance costs Payment Of Financing Insurance Principal payment of financed insurance Gross proceeds Proceeds from issuance of stock, net of issuance costs Gross proceeds Proceeds from Stock Options Exercised Proceeds from exercise of stock options Net Cash Provided by (Used in) Financing Activities Net cash used in financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net decrease in cash and cash equivalents SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION CASH PAID FOR: Supplemental disclosure of cash flow information: Interest Cash paid for interest Income Taxes. Cash paid for income taxes NON CASH FINANCING ACTIVITIES: Non-cash investing and financing activities: Future cash outflow to pay for deferred offering cost that has been occured. Deferred offering costs, accrued but not yet paid Deferred offering costs, accrued but not yet paid Capital Expenditures Incurred but Not yet Paid Capital expenditures in accounts payable Organization and Description of Business BASIS OF PRESENTATION Organization and Description of Business Significant Accounting Policies The entire disclosure for all significant accounting policies and going concern of the reporting entity. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GOING CONCERN Significant Accounting Policies n/a Liquidity The entire disclosure of liquidity, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Liquidity [Text Block] Liquidity Other Prepaid Expenses and Other Current Assets The entire disclosure on other prepaid expenses and other current assets. Other Prepaid, and Other Current Assets Disclosure [Text Block] Other Prepaid Expenses and Other Current Assets Equipment Property, Plant and Equipment Disclosure [Text Block] Equipment Investment Equity Method Investments and Joint Ventures Disclosure [Text Block] Investment Accrued Expenses and Other Current Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued Expenses and Other Current Liabilities Fair Value Fair Value Disclosures [Text Block] Fair Value Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Stock-Based Compensation Share-based Payment Arrangement [Text Block] Stock-Based Compensation Commitments and Contingencies COMMITMENTS AND CONTINGENCIES. Commitments and Contingencies Subsequent Events Subsequent Events [Text Block] Subsequent Events Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Use of Estimates Use of Estimates Fair Value Measurements Fair Value Measurements Marketable Securities, Policy [Policy Text Block] Marketable Securities Net Loss Per Share Recent Accounting Pronouncements Recent Accounting Pronouncements Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of anti dilutive securities excluded from the computation of diluted weighted average shares Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Summary of other prepaid expenses and current assets Property, Plant and Equipment [Table Text Block] Schedule of equipment Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses and other current liabilities Schedule of fair value hierarchy for its warrant liabilities measured at fair value Schedule of assumptions were used in determining the fair value of the warrant liabilities Schedule of change in fair value of the warrant liabilities Schedule of warrants issued and outstanding Schedule of warrants issued and outstanding Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of stock-based compensation expense Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block] Summary of stock options issued and outstanding Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of key assumptions used to estimate the fair value of the stock options granted Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Summary of changes in the outstanding restricted stock N/A. Asset Acquisition Line Items [Abstract] Payments to Acquire Productive Assets Consideration in cash Number of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition. Asset Acquisition, Consideration Transferred, Number of Shares Consideration in shares of Common Stock Number of acquirer's equity interest issued as part of consideration transferred in asset acquisition. Asset Acquisition, Consideration Transferred, Number of Shares Issued Consideration in shares of Common Stock issued Number of acquirer's equity interest issuable and held in escrow as part of consideration transferred in asset acquisition. Asset Acquisition, Consideration Transferred, Number of Shares Held in Escrow Consideration in shares of Common Stock held in escrow Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Marketable Securities [Abstract] Marketable Securities Marketable Securities Marketable securities Potentially dilutive (warrants and options) excluded from computation diluted loss per share Antidilutive securities excluded from computation of earnings per share (in shares) Schedule that describes about organization and description of business. Organization and Description of Business [Table] Condensed Balance Sheet Statements, Captions [Line Items] Number of new stock issued during the period. Stock Issued During Period Shares New Issues Additional Shares Stock Issued During Period, Shares, New Issues, Additional Shares Stock Issued During Period, Shares, New Issues, Additional Shares Shares Issued, Price Per Share Shares Issued, Price Per Share Shares Issued, Price Per Share Amount of asset related to consideration paid in advance for research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer. Prepaid Research and Development Expense Prepaid research and development expense Prepaid Rent Prepaid rent Other Prepaid Expense, Current Other prepaid expenses and other current assets Property, Plant and Equipment, Gross Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated depreciation Depreciation Depreciation Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Line Items] Equity Method Investment, Ownership Percentage Percentage of ownership held Fair value of common stock of equity method investments assumed in connection with a business combination transaction. Equity Method Investments, Fair Value Of Common Stock Assumed Fair value of DepYmed common shares assumed in connection with acquisition of Ohr Amount of income (loss) for proportionate share of equity method investee's income (loss). Income Loss From Equity Method Investment Equity in losses on equity method investment Number of board of director seats held by the Company. Number Of Board Of Directors Seats Held Number of board of directors seats held Number of board of director seats available in the joint venture. Number Of Board Of Directors Seats Available Total number of board of directors seats Equity Method Investments Carrying amount of the investment Accrued Employee Benefits, Current Accrued compensation and benefits Carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting settlement. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Consulting Settlement, Current Accrued consulting settlement Accrued Professional Fees, Current Accrued professional fees Carrying value as of the balance sheet date of accrued research and development. Accrued Research and Development Current Accrued research and development Amount of accrued franchise tax. Accrued Franchise Tax Accrued franchise tax Carrying value as of the balance sheet date of obligations incurred through that date and payable for patent expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Patent Expenses, Current Accrued patent expenses Other Accrued Liabilities, Current Other accrued expenses EX-101.PRE 10 nbse-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Mar. 31, 2021	May 12, 2021
Document and Entity Information
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Entity File Number	333-88480
Entity Registrant Name	NEUBASE THERAPEUTICS, INC.
Entity Incorporation, State Code	DE
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	NBSE
Security Exchange Name	NASDAQ
Entity's Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		32,716,827
Entity Central Index Key	0001173281
Current Fiscal Year End Date	--09-30
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Amendment Flag	false

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2021	Sep. 30, 2020
CURRENT ASSETS
Cash and cash equivalents	$ 24,246,752	$ 31,992,283
Prepaid insurance	256,985	521,617
Other prepaid expenses and current assets	436,394	294,640
Total Current Assets	24,940,131	32,808,540
EQUIPMENT, net	1,652,510	1,166,934
OTHER ASSETS
Investment	578,742	323,557
Long-term prepaid insurance	48,416	145,250
Security deposit	253,565
Total Other Assets	880,723	468,807
TOTAL ASSETS	27,473,364	34,444,281
CURRENT LIABILITIES
Accounts payable	2,175,792	1,505,042
Accrued expenses and other current liabilities	1,130,343	555,883
Warrant liabilities	229,442	950,151
Insurance note payable		138,557
Total Liabilities	3,535,577	3,149,633
COMMITMENTS AND CONTINGENCIES
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2020 and September 30, 2020	0	0
Common stock, $0.0001 par value; 250,000,000 shares authorized; 23,177,591 and 23,154,084 shares issued and outstanding as of December 31,2020 and September 30, 2020, respectively	2,317	2,315
Additional paid-in capital	77,082,072	74,850,935
Accumulated deficit	(53,146,602)	(43,558,602)
Total stockholders' equity	23,937,787	31,294,648
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 27,473,364	$ 34,444,281

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2021	Sep. 30, 2020
Condensed Consolidated Balance Sheets
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized	250,000,000	250,000,000
Common stock, issued	23,180,024	23,154,084
Common stock, outstanding	23,180,024	23,154,084

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
OPERATING EXPENSES
General and administrative	$ 2,721,640	$ 2,739,021	$ 5,363,110	$ 5,293,701
Research and development	3,174,129	1,616,009	5,194,053	2,843,695
TOTAL OPERATING EXPENSES	5,895,769	4,355,030	10,557,163	8,137,396
LOSS FROM OPERATIONS	(5,895,769)	(4,355,030)	(10,557,163)	(8,137,396)
OTHER INCOME (EXPENSE)
Interest expense	(6,460)	(342)	(16,197)	(1,653)
Interest income	9,466		9,466
Change in fair value of warrant liabilities	90,597	69,944	720,709	(624,190)
Equity in losses on equity method investment	(36,127)	(92,842)	(61,539)	(117,351)
Other income (expense)	316,724		316,724	(3,230)
Total other income (expenses), net	374,200	(23,240)	969,163	(746,424)
NET LOSS	$ (5,521,569)	$ (4,378,270)	$ (9,588,000)	$ (8,883,820)
BASIC AND DILUTED LOSS PER SHARE (in dollars per share)	$ (0.24)	$ (0.26)	$ (0.41)	$ (0.52)
WEIGHTED AVERAGE SHARES OUTSTANDING:
BASIC AND DILUTED	23,179,646	17,075,875	23,176,877	17,073,765

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance, beginning at Sep. 30, 2019	$ 1,708	$ 36,201,758	$ (26,174,082)	$ 10,029,384
Balance, beginning, shares at Sep. 30, 2019	17,077,873
Stock-based compensation expense		2,843,636		2,843,636
Issuance of restricted stock for services (in shares)	2,752
Net loss			(8,883,820)	(8,883,820)
Balance, ending at Mar. 31, 2020	$ 1,708	39,045,394	(35,057,902)	3,989,200
Balance, ending, shares at Mar. 31, 2020	17,080,625
Balance, beginning at Dec. 31, 2019	$ 1,708	37,705,984	(30,679,632)	7,028,060
Balance, beginning, shares at Dec. 31, 2019	17,077,873
Stock-based compensation expense		1,339,410		1,339,410
Issuance of restricted stock for services	$ 2,752
Net loss			(4,378,270)	(4,378,270)
Balance, ending at Mar. 31, 2020	$ 1,708	39,045,394	(35,057,902)	3,989,200
Balance, ending, shares at Mar. 31, 2020	17,080,625
Balance, beginning at Sep. 30, 2020	$ 2,315	74,850,935	(43,558,602)	$ 31,294,648
Balance, beginning, shares at Sep. 30, 2020	23,154,084			23,154,084
Stock-based compensation expense	$ 0	2,118,693	0	$ 2,118,693
Issuance of restricted stock for services (in shares)	4,364
Exercise of stock options	$ 2	112,444		$ 112,446
Exercise of stock options (in shares)	21,576			21,576
Net loss	$ 0	0	(9,588,000)	$ (9,588,000)
Balance, ending at Mar. 31, 2021	$ 2,317	77,082,072	(53,146,602)	$ 23,937,787
Balance, ending, shares at Mar. 31, 2021	23,180,024			23,180,024
Balance, beginning at Dec. 31, 2020	$ 2,317	76,139,964	(47,625,033)	$ 28,517,248
Balance, beginning, shares at Dec. 31, 2020	23,177,591
Stock-based compensation expense		942,108		942,108
Issuance of restricted stock for services (in shares)	2,433
Net loss			(5,521,569)	(5,521,569)
Balance, ending at Mar. 31, 2021	$ 2,317	$ 77,082,072	$ (53,146,602)	$ 23,937,787
Balance, ending, shares at Mar. 31, 2021	23,180,024			23,180,024

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (9,588,000)	$ (8,883,820)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation	2,118,693	2,843,636
Change in fair value of warrant liabilities	(720,709)	624,190
Depreciation and amortization	151,418	199,500
Loss on marketable security	(15,006)	0
Loss on disposal of fixed asset	0	(3,230)
Equity in losses on equity method investment	61,539	117,351
Gain on sale of intellectual property	(316,724)	0
Changes in operating assets and liabilities
Prepaid insurance, other expenses and current assets	122,878	214,698
Long-term prepaid insurance	96,834	96,833
Security Deposit	(253,565)	0
Accounts payable	436,646	186,911
Accrued expenses and other current liabilities	574,460	340,288
Net cash used in operating activities	(7,301,524)	(4,257,183)
Cash flows from investing activities
Purchase of laboratory and office equipment	(402,890)	(161,916)
Purchase of marketable securities	(44,990,079)	0
Sale of marketable securities	44,975,073	0
Net cash used in investing activities	(417,896)	(161,916)
Cash flows from financing activities
Principal payment of financed insurance	(138,557)	(122,919)
Proceeds from exercise of stock options	112,446	0
Net cash used in financing activities	(26,111)	(122,919)
Net decrease in cash and cash equivalents	(7,745,531)	(4,542,018)
Cash and cash equivalents, beginning of period	31,992,283	10,313,966
Cash and cash equivalents, end of period	24,246,752	5,771,948
Supplemental disclosure of cash flow information:
Cash paid for interest	10,400	1,668
Cash paid for income taxes	0	0
Non-cash investing and financing activities:
Deferred offering costs, accrued but not yet paid	0	196,724
Capital expenditures in accounts payable	$ 234,104	$ 0

XML 17 R7.htm IDEA: XBRL DOCUMENT

Organization and Description of Business	6 Months Ended
Organization and Description of Business	Mar. 31, 2021
Organization and Description of Business
Organization and Description of Business	1. Organization and Description of Business NeuBase Therapeutics, Inc. and subsidiaries (the “Company” or “NeuBase”) is developing a modular peptide-nucleic acid (“PNA”) antisense oligo (“PATrOL™”) platform to address genetic diseases caused by mutant proteins, with a single, cohesive approach. The PATrOL™-enabled anti-gene therapies are designed to improve upon current genetic medicine strategies by combining the advantages of synthetic approaches with the precision of antisense technologies. NeuBase plans to use its platform to address diseases which have a genetic source, with an initial focus on Huntington’s Disease (“HD”) and Myotonic Dystrophy Type 1 (“DM1”), as well as other genetic disorders and cancer. NeuBase is a pre-clinical-stage biopharmaceutical company and continues to develop its clinical and regulatory strategy with its internal research and development team with a view toward prioritizing market introduction as quickly as possible. NeuBase’s lead programs are NT0100 and NT0200. The NT0100 program is a PATrOL™-enabled therapeutic program being developed to target the mutant expansion in the HD messenger ribonucleic acid (“RNA”). The NT0100 program includes several proprietary PNAs which have the potential to be highly selective for the mutant transcript vs. the wild-type transcribed allele and the expectation to be applicable for all HD patients as it directly targets the expansion itself, and has the potential to be delivered systemically. PATrOL™-enabled drugs also have the unique ability to open RNA secondary structures and bind to either the primary nucleotide sequences or the secondary and/or tertiary structures. NeuBase believes the NT0100 program addresses an unmet need for a disease which currently has no effective therapeutics that target the core etiology of the condition. NeuBase believes there is a large opportunity in the U.S. and European markets for drugs in this space. The NT0200 program is a PATrOL™-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease mRNA. The NT0200 program includes several proprietary PNAs which have the potential to be highly selective for the mutant transcript versus the wild-type transcribed allele and the expectation to be effective for nearly all DM1 patients as it directly targets the expansion itself. NeuBase believes the NT0200 program addresses an unmet need for a disease which currently has no effective therapeutics that target the core etiology of the condition. NeuBase believes there is also a large opportunity in the U.S. and European markets for drugs in this space. Acquisition On January 27, 2021, we entered into an Asset Purchase Agreement by and among us, NeuBase Corporation, our wholly owned subsidiary, and Vera Therapeutics, Inc. ("Vera") as amended by the Amendment to Asset Purchase Agreement, dated as of April 20, 2021, by and between the Company and Vera (collectively, the "APA"). Pursuant to the terms of the APA, we acquired infrastructure, materials, and intellectual property for peptide-nucleic acid ("PNA") scaffolds from Vera for total consideration of approximately $0.8 million in cash and 308,635 shares of Common Stock (of which 146,375 were to be issued to Vera and 162,260 will be held in escrow and released to Vera in accordance with the terms of an escrow agreement between NeuBase Corporation and Vera). The transaction closed on April 26, 2021, and we issued the shares to Vera on that date.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

6 Months Ended

Mar. 31, 2021

Significant Accounting Policies

Significant Accounting Policies

2. Significant Accounting Policies

Basis of Presentation

Use of Estimates

The Company assesses and updates estimates each period to reflect current information, such as the economic considerations related to the impact that the novel coronavirus disease (“COVID-19”) could have on our significant accounting estimates (see Part II, Item 1A – Risk Factors—“Our operations may be adversely affected by the coronavirus outbreak, and we face risks that could impact our business” for further discussion of the effect of the COVID-19 pandemic on our operations). Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.

Fair Value Measurements

Level 1 – Quoted prices in active markets for identical assets or liabilities on the reporting date.

Marketable Securities

Net Loss Per Share


	As of March 31,
	2021	2020
Common stock purchase options	6,552,884	6,506,966
Unvested restricted stock	—	3,125
Common stock purchase warrants	820,939	715,939
	7,373,823	7,226,030

Recent Accounting Pronouncements

XML 19 R9.htm IDEA: XBRL DOCUMENT

Liquidity	6 Months Ended
Liquidity	Mar. 31, 2021
Liquidity
Liquidity	3. Liquidity The Company has had no revenues from product sales and has incurred operating losses since inception. As of March 31, 2021, the Company had $24.2 million in cash and cash equivalents and during the six months ended March 31, 2021, incurred a loss from operations of $10.6 million and used $7.3 million of cash in operating activities. The Company has historically funded its operations primarily through the sale of common stock. On April 26, 2021, the Company closed on an underwritten public offering of you shares of its common stock (inclusive of 1,200,000 shares that were sold pursuant to the underwriters' full exercise of their option to purchase additional shares of the Company's common stock), at a price to the public of $5.00 per share. The Company expects that the net proceeds from the offering will be approximately $42.6 million, after deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company. The Company expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As a result, the Company will likely need to raise additional capital through one or more of the following: issuance of additional debt or equity, or complete a licensing transaction for one or more of the Company’s pipeline assets. Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these unaudited condensed consolidated financial statements were available to be issued. There can be no assurance that the Company will be successful in acquiring additional funding, that the Company's projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.

XML 20 R10.htm IDEA: XBRL DOCUMENT

Other Prepaid Expenses and Other Current Assets

6 Months Ended

Mar. 31, 2021

Other Prepaid Expenses and Other Current Assets

Other Prepaid Expenses and Other Current Assets

4. Other Prepaid Expenses and Other Current Assets

The Company’s prepaid expenses and other current assets consisted of the following:


	As of March 31,		As of September 30,
	2021		2020
Prepaid research and development expense	$	29,422	$	205,641
Prepaid rent		301,481		—
Other prepaid expenses and other current assets		105,491		88,999
Total	$	436,394	$	294,640

XML 21 R11.htm IDEA: XBRL DOCUMENT

Equipment

6 Months Ended

Mar. 31, 2021

Equipment

Equipment

5. Equipment

The Company’s equipment consisted of the following:


	As of March 31,		As of September 30,
	2021		2020
Laboratory equipment	$	1,825,393	$	1,319,123
Office equipment		137,201		6,477
Total		1,962,594		1,325,600
Accumulated depreciation		(310,084)		(158,666)
Property, plant and equipment, net	$	1,652,510	$	1,166,934

Depreciation expense for the three months ended March 31, 2021 and 2020 was approximately $0.08 million and $0.03, respectively. Depreciation expense for the six months ended March 31, 2021 and 2020 was approximately $0.15 million and $0.05, respectively.

XML 22 R12.htm IDEA: XBRL DOCUMENT

Investment	6 Months Ended
Investment	Mar. 31, 2021
Investment
Investment	6. Investment The Company owns common and preferred shares of DepYmed, Inc. (“DepYmed”), which in aggregate represents approximately 13% ownership of DepYmed and includes recently acquired DepYmed Series A-4 preferred shares with a fair value of approximately $0.3 million that were issued to the Company in February 2021 in exchange for the Company's sale of certain intellectual property. In addition, the Company is entitled to hold one of the six seats on DepYmed’s board of directors. The Company accounts for its investment in DepYmed common shares using the equity method of accounting and records its proportionate share of DepYmed’s net income and losses in the accompanying unaudited condensed consolidated statements of operations. Equity in losses for the three months ended March 31, 2021 and 2020 were approximately $0.04 million and $0.01 million, respectively. Equity in losses for the six months ended March 31, 2021 and 2020 were approximately $0.06 million and $0.01 million, respectively. The Company accounts for its investment in preferred shares of DepYmed at cost, less any impairment, as the Company determined the preferred stock did not have a readily determinable fair value. As of both March 31, 2021 and September 30, 2020, the carrying amount of the Company’s aggregate investment in DepYmed was $0.6 million and $0.3 million, respectively.

XML 23 R13.htm IDEA: XBRL DOCUMENT

Accrued Expenses and Other Current Liabilities

6 Months Ended

Mar. 31, 2021

Accrued Expenses and Other Current Liabilities

Accrued Expenses and Other Current Liabilities

7. Accrued Expenses and Other Current Liabilities

The Company’s accrued expenses and other current liabilities consisted of the following:


	As of March 31,		As of September 30,
	2021		2020
Accrued compensation and benefits	$	153,688	$	88,527
Accrued consulting settlement		250,000		—
Accrued professional fees		167,829		241,755
Accrued research and development		217,701		41,313
Accrued franchise tax		79,088		155,865
Accrued patent expenses		258,331		24,716
Other accrued expenses		3,706		3,707
Total	$	1,130,343	$	555,883

XML 24 R14.htm IDEA: XBRL DOCUMENT

Fair Value

6 Months Ended

Mar. 31, 2021

Fair Value

Fair Value

8. Fair Value

The following tables present the Company’s fair value hierarchy for its warrant liabilities measured at fair value on a recurring basis at March 31, 2021 and September 30, 2020:


	Fair Value Measurements
	as of March 31, 2021
	(Level 1)		(Level 2)		(Level 3)		Total
Liabilities
Warrant liabilities	$	—		—		229,442	$	229,442

	Fair Value Measurements
	as of September 30, 2020
	(Level 1)		(Level 2)		(Level 3)		Total
Liabilities
Warrant liabilities	$	—		—		950,151	$	950,151

The fair value of the warrant liabilities were determined using the Black-Scholes option pricing model. The following assumptions were used in determining the fair value of the warrant liabilities :


	As of March 31,
	2021	2020
Remaining contractual term (years)	0.7 - 1.0	1.7 - 2.0
Common stock price volatility	69.5% - 71.4%	89.6% - 92.5%
Risk-free interest rate	0.07%	0.23%
Expected dividend yield	—	—

The Company was historically a private company and lacked company-specific historical and implied volatility information, therefore the Company estimated its expected stock volatility based on the historical volatility of a set of publicly traded peer companies. During the three and six months ended March 31, 2021, the Company utilized its historical volatility in the valuation of warrant liabilities as it had sufficient trading history.

The change in fair value of the warrant liabilities for the three and six months ended March 31,2021 and 2020 is as follows:


Fair value as of September 30, 2020	$	950,151
Change in fair value		(630,112)
Fair value as of December 31, 2020		320,039
Change in fair value		(90,597)
Fair value as of March 31, 2021	$	229,442

Fair value as of September 30, 2019	$	496,343
Change in fair value		694,134
Fair value as of December 31, 2019		1,190,477
Change in fair value		(69,944)
Fair value as of March 31, 2020	$	1,120,533

As of March 31, 2021 and September 30, 2020, the recorded values of cash and cash equivalents, accounts payable and the insurance note payable approximate fair value due to the short-term nature of these instruments.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 25 R15.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

6 Months Ended

Mar. 31, 2021

Stockholders' Equity

Stockholders' Equity

9. Stockholders’ Equity

Warrants

Below is a summary of the Company’s issued and outstanding warrants as of March 31, 2021:


			Warrants
Expiration date	Exercise Price		Outstanding
December 13, 2021	$	55.00	20,627
April 10, 2022		20.00	695,312
July 6, 2023		8.73	105,000
			820,939


				Weighted
		Weighted		Average
		Average		Remaining
		Exercise		Contractual Life
	Warrants	Price		(in years)
Outstanding as of September 30, 2020	820,939	$	19.44
Outstanding as of March 31, 2021	820,939		19.44	1.2
Exercisable as of March 31, 2021	820,939		19.44	1.2

XML 26 R16.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

6 Months Ended

Mar. 31, 2021

Stock-Based Compensation

Stock-Based Compensation

10. Stock-Based Compensation


		Three Months ended March 31,			Six Months ended March 31,
	2021		2020		2021		2020
General and administrative	$	448,880	$	954,241	$	1,291,159	$	2,067,352
Research and development		493,228		385,169		827,534		776,284
Total	$	942,108	$	1,339,410	$	2,118,693	$	2,843,636

Stock Options

Below is a table summarizing the options issued and outstanding as of and for the six months ended March 31, 2021:


				Weighted
		Weighted		Average	Total
		Average		Remaining	Aggregate
		Exercise		Contractual Life	Intrinsic
	Stock Options	Price		(in years)	Value
Outstanding at September 30, 2020	6,190,790	$	2.76
Granted	534,340		7.59
Exercised	(21,576)		5.21
Forfeited	(150,670)		5.68
Outstanding at March 31, 2021	6,552,884		3.08	8.1	$	29,219,357
Exercisable as of March 31, 2021	4,575,375		1.65	7.7	$	26,884,291

As of March 31, 2021, unrecognized compensation costs associated with the stock options of $4.8 million will be recognized over an estimated weighted-average amortization period of 1.3 years.

The weighted average grant date fair value of options granted during the six months ended March 31, 2021 and 2020 was $5.32 and $4.78, respectively.

Key assumptions used to estimate the fair value of the stock options granted during the six months ended March 31, 2021 and 2020 included:


	Six Months ended March 31,
	2021	2020

Expected term of options (years)	5.5 - 7.0	7.0
Expected common stock price volatility	83% - 83.3%	78% - 83.5%
Risk-free interest rate	0.6% - 1.3%	0.9% - 1.8%
Expected dividend yield	—	—

During the six months ended March 31, 2021, the Company granted a stock option to purchase 225,000 shares to a consultant in recognition of future service to the Company as an employee. The exercisability and vesting of the stock options are subject to the consultant's effective date of employment with the Company, which has not yet occurred as of March 31, 2021, and as a result, the grant-date of such option has not occurred under GAAP. Therefore, the number and fair value of the shares subject to this option are not reflected in the table summarizing the options issued and outstanding as of and for the six months ended March 31, 2021 and did not have impact on unrecognized compensation costs or the estimated weighted-average amortization period above as of March 31, 2021.

Restricted Stock

A summary of the changes in the unvested restricted stock during the six months ended March 31, 2021 is as follows:


			Weighted
			Average
			Grant Date
	Unvested Restricted		Fair Value
	Stock		Price
Unvested as of September 30, 2020		—	$	—
Granted		4,364		9.17
Vested		(4,364)		9.17
Unvested as of March 31, 2021		—		—

XML 27 R17.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Mar. 31, 2021
Commitments and Contingencies
Commitments and Contingencies	11. Commitments and Contingencies Operating Leases In October 2020, the Company entered into a ten-year lease agreement with annual escalating rental payments for office and laboratory space in Pittsburgh, Pennsylvania. The leased premises will serve as the Company’s headquarters upon the commencement of the lease. The initial term of the lease commences upon the landlord’s delivery of the leased premises in tenant improvement readiness condition, which occurred on May 1, 2021. The initial term of the lease will extend approximately ten years from delivery of the leased premises to the Company, unless earlier terminated in accordance with the lease. The Company has the right to extend the term of the lease for an additional five-year term. Under the lease, the Company will lease approximately 14,189 square feet of the property. Pursuant to amendment 1 to the lease agreement during December 2020, and amendment 2 to the lease agreement in April 2021, the Company will pay an escalating base rent over the life of the lease of approximately $71,000 to $78,000 per month, and the Company will pay its pro rata portion of property expenses and operating expenses for the property. The Company will measure and recognize the right-of-use (“ROU”) asset and operating lease liability upon lease commencement. During the six months ended March 31, 2021, the Company prepaid rent of $0.3 million and paid a security deposit of $0.3 million for this lease agreement. The Company currently leases its existing office and operating space under operating leases with original terms of less than 12 months and which expire at various dates through November 2021; therefore, the Company’s operating leases are not recognized as ROU assets on the unaudited condensed consolidated balance sheet as of March 31, 2021. Rent expense under the Company’s operating leases totaled approximately $0.03 million and $0.02 million for the three months ended March 31, 2021 and 2020, respectively. Rent expense under the Company's operating leases totaled approximately $0.06 million and $0.04 million for the six months ended March 31, 2021 and 2020, respectively. The Company continues to operate under its current operating lease in Pittsburgh on a month-to-month basis and will continue to operate under the lease until the Company moves into its new headquarters and laboratory space, which is expected to occur in June 2021. All terms and conditions remain the same from the current lease. In November 2020, the Company extended the term of its rental of office space in New York until November 2021. Litigation The Company has become involved in certain legal proceedings and claims which arise in the normal course of business. If an unfavorable ruling were to occur, there exists the possibility of a material adverse impact on the Company’s results of operations, prospects, cash flows, financial position and brand. On February 14, 2018, plaintiff Jeevesh Khanna, commenced an action in the Southern District of New York, against Ohr and several current and former officers and directors, alleging that they violated federal securities laws between June 24, 2014 and January 4, 2018. On August 7, 2018, the lead plaintiffs, now George Lehman and Insured Benefit Plans, Inc., filed an amended complaint, stating the class period to be April 8, 2014 through January 4, 2018. The plaintiffs did not quantify any alleged damages in their complaint but, in addition to attorneys’ fees and costs, they seek to maintain the action as a class action and to recover damages on behalf of themselves and other persons who purchased or otherwise acquired Ohr common stock during the putative class period and purportedly suffered financial harm as a result. We and the individuals dispute these claims and intend to defend the matter vigorously. On September 17, 2018, Ohr filed a motion to dismiss the complaint. On September 20, 2019, the district court entered an order granting the defendants’ motion to dismiss. On October 23, 2019, the plaintiffs filed a notice of appeal of that order dismissing the action and other related orders by the district court. After full briefing and oral argument, on October 9, 2020, the U.S. Court of Appeals for the Second Circuit issued a summary order affirming the district court’s order granting the motion to dismiss and remanding the action to the district court to make a determination on the record related to plaintiffs’ request for leave to file an amended complaint. On October 16, 2020, the district court requested the parties’ positions as to how they proposed to proceed in light of the Second Circuit’s decision. After letter briefing on this issue and plaintiffs’ alternative request for leave to file a second amended complaint, on November 16, 2020, the district court denied plaintiffs’ request to amend and dismissed with prejudice plaintiffs’ claims. On December 16, 2020, plaintiffs filed a notice of appeal of that order denying plaintiffs leave to amend, and the plaintiffs filed their appellate brief with respect to such matters with the Court on March 31, 2021. This litigation could result in substantial costs and a diversion of management’s resources and attention, which could harm the Company’s business and the value of the Company's common stock. On May 3, 2018, plaintiff Adele J. Barke, derivatively on behalf of Ohr, commenced an action against certain former directors of Ohr, including Michael Ferguson, Orin Hirschman, Thomas M. Riedhammer, June Almenoff and Jason S. Slakter in the Supreme Court, State of New York, alleging that the action was brought in the right and for the benefit of Ohr seeking to remedy their “breach of fiduciary duties, corporate waste and unjust enrichment that occurred between June 24, 2014 and the present.” It does not quantify any alleged damages. We and the individuals dispute these claims and intend to defend the matter vigorously. Such litigation has been stayed pursuant to a stipulation by the parties, which has been so ordered by the court, pending a decision in the Southern District case on the motion to dismiss, but that status could change. This litigation could result in substantial costs and a diversion of management’s resources and attention, which could harm our business and the value of our common stock. On March 20, 2019, a putative class action lawsuit was filed in the United States District Court for District of Delaware naming as defendants Ohr and its board of directors, Legacy NeuBase and Ohr Acquisition Corp., captioned Wheby v. Ohr Pharmaceutical, Inc., et al., Case No. 1:19-cv-00541-UNA (the “Wheby Action”). The plaintiffs in the Wheby Action allege that the preliminary joint proxy/prospectus statement filed by Ohr with the SEC on March 8, 2019 contained false and misleading statements and omitted material information in violation of Section 14(a) of the Exchange Act and SEC Rule 14a-9 promulgated thereunder, and further that the individual defendants are liable for those alleged misstatements and omissions under Section 20(a) of the Exchange Act. The complaint in the Wheby Action has not been served on, nor was service waived by, any of the named defendants in that action. The action seeks, among other things, to rescind the Merger or an award of damages, and an award of attorneys’ and experts’ fees and expenses. The defendants dispute the claims raised in the Wheby Action. Management believes that the likelihood of an adverse decision from the sole remaining action is unlikely; however, the litigation could result in substantial costs and a diversion of management’s resources and attention, which could harm our business and the value of our common stock.

XML 28 R18.htm IDEA: XBRL DOCUMENT

Subsequent Events	6 Months Ended
Subsequent Events	Mar. 31, 2021
Subsequent Events
Subsequent Events	12. Subsequent Events On April 21, 2021, the Company entered into a second amendment (the "Second Amendment") to the Lease Agreement (as amended, the "Lease") with 350 Technology Drive Partners, LLC (the "Landlord") for office and laboratory space (the "Leased Premises") located at 350 Technology Drive, Pittsburgh, Pennsylvania. Pursuant to the Second Amendment, the parties amended the Lease to provide that the Lease will commence on May 1, 2021. On such date, the Company is obligated to begin making rental payments, provided that the Company may be entitled to a rental credit for certain periods based on the date the Landlord delivers possession of the office space and biology lab within the Leased Premises to the Company and the date the Landlord substantially completes tenant improvements. In addition, pursuant to the Second Amendment and as a result of approved change orders, the Company will pay an escalating base rent over the life of the Lease of approximately $71,000 to $78,000 per month. Refer to the discussion in Note 10. On April 26, 2021, the Company closed on an underwritten public offering of 9,200,000 shares of its common stock (inclusive of 1,200,000 shares that were sold pursuant to the underwriters' full exercise of their option to purchase additional shares of the Company's common stock), at a price to the public of $5.00 per share. Refer to the discussion in Note 3. On April 26, 2021, the Company closed the Vera transaction. Refer to the discussion in Note 1. [Open]

XML 29 R19.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

6 Months Ended

Mar. 31, 2021

Significant Accounting Policies

Basis of Presentation

Use of Estimates

The Company assesses and updates estimates each period to reflect current information, such as the economic considerations related to the impact that the novel coronavirus disease (“COVID-19”) could have on our significant accounting estimates (see Part II, Item 1A – Risk Factors—“Our operations may be adversely affected by the coronavirus outbreak, and we face risks that could impact our business” for further discussion of the effect of the COVID-19 pandemic on our operations). Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.

Fair Value Measurements

Level 1 – Quoted prices in active markets for identical assets or liabilities on the reporting date.

Marketable Securities

Net Loss Per Share


	As of March 31,
	2021	2020
Common stock purchase options	6,552,884	6,506,966
Unvested restricted stock	—	3,125
Common stock purchase warrants	820,939	715,939
	7,373,823	7,226,030

Recent Accounting Pronouncements

XML 30 R20.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Tables)

6 Months Ended

Mar. 31, 2021

Significant Accounting Policies

Schedule of anti dilutive securities excluded from the computation of diluted weighted average shares


	As of March 31,
	2021	2020
Common stock purchase options	6,552,884	6,506,966
Unvested restricted stock	—	3,125
Common stock purchase warrants	820,939	715,939
	7,373,823	7,226,030

XML 31 R21.htm IDEA: XBRL DOCUMENT

Other Prepaid Expenses and Other Current Assets (Tables)

6 Months Ended

Mar. 31, 2021

Other Prepaid Expenses and Other Current Assets

Summary of other prepaid expenses and current assets


	As of March 31,		As of September 30,
	2021		2020
Prepaid research and development expense	$	29,422	$	205,641
Prepaid rent		301,481		—
Other prepaid expenses and other current assets		105,491		88,999
Total	$	436,394	$	294,640

XML 32 R22.htm IDEA: XBRL DOCUMENT

Equipment (Tables)

6 Months Ended

Mar. 31, 2021

Equipment

Schedule of equipment


	As of March 31,		As of September 30,
	2021		2020
Laboratory equipment	$	1,825,393	$	1,319,123
Office equipment		137,201		6,477
Total		1,962,594		1,325,600
Accumulated depreciation		(310,084)		(158,666)
Property, plant and equipment, net	$	1,652,510	$	1,166,934

XML 33 R23.htm IDEA: XBRL DOCUMENT

Accrued Expenses and Other Current Liabilities (Tables)

6 Months Ended

Mar. 31, 2021

Accrued Expenses and Other Current Liabilities

Schedule of accrued expenses and other current liabilities


	As of March 31,		As of September 30,
	2021		2020
Accrued compensation and benefits	$	153,688	$	88,527
Accrued consulting settlement		250,000		—
Accrued professional fees		167,829		241,755
Accrued research and development		217,701		41,313
Accrued franchise tax		79,088		155,865
Accrued patent expenses		258,331		24,716
Other accrued expenses		3,706		3,707
Total	$	1,130,343	$	555,883

XML 34 R24.htm IDEA: XBRL DOCUMENT

Fair Value (Tables)

6 Months Ended

Mar. 31, 2021

Fair Value

Schedule of fair value hierarchy for its warrant liabilities measured at fair value


	Fair Value Measurements
	as of March 31, 2021
	(Level 1)		(Level 2)		(Level 3)		Total
Liabilities
Warrant liabilities	$	—		—		229,442	$	229,442

	Fair Value Measurements
	as of September 30, 2020
	(Level 1)		(Level 2)		(Level 3)		Total
Liabilities
Warrant liabilities	$	—		—		950,151	$	950,151

Schedule of assumptions were used in determining the fair value of the warrant liabilities


	As of March 31,
	2021	2020
Remaining contractual term (years)	0.7 - 1.0	1.7 - 2.0
Common stock price volatility	69.5% - 71.4%	89.6% - 92.5%
Risk-free interest rate	0.07%	0.23%
Expected dividend yield	—	—

Schedule of change in fair value of the warrant liabilities


Fair value as of September 30, 2020	$	950,151
Change in fair value		(630,112)
Fair value as of December 31, 2020		320,039
Change in fair value		(90,597)
Fair value as of March 31, 2021	$	229,442

Fair value as of September 30, 2019	$	496,343
Change in fair value		694,134
Fair value as of December 31, 2019		1,190,477
Change in fair value		(69,944)
Fair value as of March 31, 2020	$	1,120,533

XML 35 R25.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

6 Months Ended

Mar. 31, 2021

Stockholders' Equity

Schedule of warrants issued and outstanding


			Warrants
Expiration date	Exercise Price		Outstanding
December 13, 2021	$	55.00	20,627
April 10, 2022		20.00	695,312
July 6, 2023		8.73	105,000
			820,939


				Weighted
		Weighted		Average
		Average		Remaining
		Exercise		Contractual Life
	Warrants	Price		(in years)
Outstanding as of September 30, 2020	820,939	$	19.44
Outstanding as of March 31, 2021	820,939		19.44	1.2
Exercisable as of March 31, 2021	820,939		19.44	1.2

XML 36 R26.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

6 Months Ended

Mar. 31, 2021

Stock-Based Compensation

Schedule of stock-based compensation expense


		Three Months ended March 31,			Six Months ended March 31,
	2021		2020		2021		2020
General and administrative	$	448,880	$	954,241	$	1,291,159	$	2,067,352
Research and development		493,228		385,169		827,534		776,284
Total	$	942,108	$	1,339,410	$	2,118,693	$	2,843,636

Summary of stock options issued and outstanding

Below is a table summarizing the options issued and outstanding as of and for the six months ended March 31, 2021:


				Weighted
		Weighted		Average	Total
		Average		Remaining	Aggregate
		Exercise		Contractual Life	Intrinsic
	Stock Options	Price		(in years)	Value
Outstanding at September 30, 2020	6,190,790	$	2.76
Granted	534,340		7.59
Exercised	(21,576)		5.21
Forfeited	(150,670)		5.68
Outstanding at March 31, 2021	6,552,884		3.08	8.1	$	29,219,357
Exercisable as of March 31, 2021	4,575,375		1.65	7.7	$	26,884,291

Schedule of key assumptions used to estimate the fair value of the stock options granted

Key assumptions used to estimate the fair value of the stock options granted during the six months ended March 31, 2021 and 2020 included:


	Six Months ended March 31,
	2021	2020

Expected term of options (years)	5.5 - 7.0	7.0
Expected common stock price volatility	83% - 83.3%	78% - 83.5%
Risk-free interest rate	0.6% - 1.3%	0.9% - 1.8%
Expected dividend yield	—	—

Summary of changes in the outstanding restricted stock

A summary of the changes in the unvested restricted stock during the six months ended March 31, 2021 is as follows:


			Weighted
			Average
			Grant Date
	Unvested Restricted		Fair Value
	Stock		Price
Unvested as of September 30, 2020		—	$	—
Granted		4,364		9.17
Vested		(4,364)		9.17
Unvested as of March 31, 2021		—		—

XML 37 R27.htm IDEA: XBRL DOCUMENT

Organization and Description of Business - Additional Information (Details) $ in Millions	Jan. 27, 2021 USD ($) shares
Asset Acquisition Line Items [Abstract]
Consideration in cash \| $	$ 0.8
Consideration in shares of Common Stock	308,635
Consideration in shares of Common Stock issued	146,375
Consideration in shares of Common Stock held in escrow	162,260

XML 38 R28.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Marketable Securities (Details) - USD ($)	Mar. 31, 2021	Sep. 30, 2020
Marketable Securities
Marketable securities	$ 0	$ 0

XML 39 R29.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Potentially dilutive securities outstanding (Details) - shares	6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	7,373,823	7,226,030
Common stock purchase options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	6,552,884	6,506,966
Unvested restricted stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)		3,125
Common stock purchase warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	820,939	715,939

XML 40 R30.htm IDEA: XBRL DOCUMENT

Liquidity (Details) - USD ($)		3 Months Ended		6 Months Ended
Liquidity (Details) - USD ($)	Apr. 26, 2021	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Sep. 30, 2020	Sep. 30, 2019
Condensed Balance Sheet Statements, Captions [Line Items]
Cash		$ 24,246,752	$ 5,771,948	$ 24,246,752	$ 5,771,948	$ 31,992,283	$ 31,992,283	$ 10,313,966
Loss from operations		$ (5,895,769)	$ (4,355,030)	(10,557,163)	(8,137,396)
Cash in operating activities				$ (7,301,524)	$ (4,257,183)
Subsequent Event
Condensed Balance Sheet Statements, Captions [Line Items]
Stock Issued During Period, Shares, New Issues, Additional Shares	1,200,000
Shares Issued, Price Per Share	$ 5.00
Gross proceeds	$ 42,600,000

XML 41 R31.htm IDEA: XBRL DOCUMENT

Other Prepaid Expenses and Other Current Assets (Details) - USD ($)	Mar. 31, 2021	Sep. 30, 2020
Other Prepaid Expenses and Other Current Assets
Prepaid research and development expense	$ 29,422	$ 205,641
Prepaid rent	301,481
Other prepaid expenses and other current assets	105,491	88,999
Total	$ 436,394	$ 294,640

XML 42 R32.htm IDEA: XBRL DOCUMENT

Equipment (Details) - USD ($)	Mar. 31, 2021	Sep. 30, 2020
Property, Plant and Equipment, Gross	$ 1,962,594	$ 1,325,600
Accumulated depreciation	(310,084)	(158,666)
Property, Plant and Equipment, Net	1,652,510	1,166,934
Laboratory equipment
Property, Plant and Equipment, Gross	1,825,393	1,319,123
Office equipment
Property, Plant and Equipment, Gross	$ 137,201	$ 6,477

XML 43 R33.htm IDEA: XBRL DOCUMENT

Equipment - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Equipment
Depreciation	$ 80	$ 30	$ 150	$ 50

XML 44 R34.htm IDEA: XBRL DOCUMENT

Investment (Details) $ in Thousands	3 Months Ended		6 Months Ended
Investment (Details) $ in Thousands	Mar. 31, 2021 USD ($)	Mar. 31, 2020 USD ($)	Mar. 31, 2021 USD ($) director	Mar. 31, 2020 USD ($)	Feb. 28, 2021 USD ($)	Sep. 30, 2020 USD ($)
Schedule of Equity Method Investments [Line Items]
Fair value of DepYmed common shares assumed in connection with acquisition of Ohr					$ 300
Equity in losses on equity method investment			$ 60	$ 10
Carrying amount of the investment						$ 300
DepYmed
Schedule of Equity Method Investments [Line Items]
Percentage of ownership held					13.00%
Equity in losses on equity method investment	$ 40	$ 10
Number of board of directors seats held \| director			1
Total number of board of directors seats \| director			6
Carrying amount of the investment	$ 600		$ 600

XML 45 R35.htm IDEA: XBRL DOCUMENT

Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Mar. 31, 2021	Sep. 30, 2020
Accrued Expenses and Other Current Liabilities
Accrued compensation and benefits	$ 153,688	$ 88,527
Accrued consulting settlement	250,000
Accrued professional fees	167,829	241,755
Accrued research and development	217,701	41,313
Accrued franchise tax	79,088	155,865
Accrued patent expenses	258,331	24,716
Other accrued expenses	3,706	3,707
Total	$ 1,130,343	$ 555,883

XML 46 R36.htm IDEA: XBRL DOCUMENT

Fair Value - Fair Value Measurements (Details)	3 Months Ended
Fair Value - Fair Value Measurements (Details)	Mar. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Sep. 30, 2020 USD ($)
Liabilities
Warrant liabilities	$ 229,442				$ 950,151
Change in fair value of the warrant liabilities
Fair value as of September 30	320,039	$ 950,151	$ 1,190,477	$ 496,343
Change in fair value	(90,597)	(630,112)	(69,944)	694,134
Fair value at the end	$ 229,442	$ 320,039	$ 1,120,533	$ 1,190,477
Remaining contractual term (years) \| Minimum
Liabilities
Warrants and Rights Outstanding, Term	8 months 11 days		1 year 8 months 11 days
Remaining contractual term (years) \| Maximum
Liabilities
Warrants and Rights Outstanding, Term	1 year		2 years
Common stock price volatility \| Minimum
Liabilities
Warrants and Rights Outstanding, Measurement Input	69.5		89.6
Common stock price volatility \| Maximum
Liabilities
Warrants and Rights Outstanding, Measurement Input	71.4		92.5
Risk-free interest rate
Liabilities
Warrants and Rights Outstanding, Measurement Input	0.07		0.23
Fair Value Measurements Level 3 [Member]
Liabilities
Warrant liabilities	$ 229,442				$ 950,151

XML 47 R37.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Warrants issued and outstanding (Details)	6 Months Ended
	Mar. 31, 2021 $ / shares shares
Warrants [Roll Forward]
Warrants, Outstanding at the beginning of the period	820,939
Warrants, Outstanding at the end of the period	820,939
Warrants, Exercisable at the end of the period	820,939
Weighted average exercise price, Outstanding at the beginning of the period \| $ / shares	$ 19.44
Weighted average exercise price, Outstanding at the end of the period \| $ / shares	19.44
Weighted average exercise price, Exercisable at the end of the period \| $ / shares	$ 19.44
Weighted average remaining contractual term, Outstanding at the end of the period	1 year 2 months 12 days
Weighted average remaining contractual term, Exercisable at the end of the period	1 year 2 months 12 days
December 13, 2021
Warrants [Roll Forward]
Warrants, Outstanding at the end of the period	20,627
Warrants, Exercisable at the end of the period	55.00
April 10, 2022
Warrants [Roll Forward]
Warrants, Outstanding at the end of the period	695,312
Warrants, Exercisable at the end of the period	20.00
July 6, 2023
Warrants [Roll Forward]
Warrants, Outstanding at the end of the period	105,000
Warrants, Exercisable at the end of the period	8.73

XML 48 R38.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Stock options (Details)	6 Months Ended
Stock-Based Compensation - Stock options (Details)	Mar. 31, 2021 USD ($) $ / shares shares
Stock Options
Outstanding, Beginning balance \| shares	6,190,790
Granted \| shares	534,340
Exercised \| shares	(21,576)
Forfeited \| shares	(150,670)
Outstanding, Ending balance \| shares	6,552,884
Exercisable \| shares	4,575,375
Weighted Average Exercise Price per Share
Outstanding, Beginning balance \| $ / shares	$ 2.76
Granted \| $ / shares	7.59
Exercised \| $ / shares	5.21
Forfeited \| $ / shares	5.68
Outstanding, Ending balance \| $ / shares	3.08
Exercisable \| $ / shares	$ 1.65
Weighted Average remaining contractual term (years) and Aggregate Intrinsic Value
Outstanding	8 years 1 month 6 days
Exercisable	7 years 8 months 12 days
Outstanding \| $	$ 29,219,357
Exercisable \| $	$ 26,884,291

XML 49 R39.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Key Assumptions Estimate Fair Value Of Stock Options (Details)	3 Months Ended	6 Months Ended
	Dec. 31, 2019	Mar. 31, 2021	Mar. 31, 2020
Key assumptions used to estimate the fair value of the stock options granted
Expected term of options (years)			7 years
Expected common stock price volatility, minimum	78.00%	83.00%
Expected common stock price volatility, maximum	83.50%	83.30%
Risk-free interest rate, minimum	0.90%	0.60%
Risk-free interest rate, maximum	1.80%	1.30%
Minimum
Key assumptions used to estimate the fair value of the stock options granted
Expected term of options (years)		5 years 6 months
Maximum
Key assumptions used to estimate the fair value of the stock options granted
Expected term of options (years)		7 years

XML 50 R40.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Restricted Stock (Details)	6 Months Ended
Stock-Based Compensation - Restricted Stock (Details)	Mar. 31, 2021 $ / shares shares
Unvested Restricted Stock
Granted \| shares	4,364
Vested \| shares	(4,364)
Weighted-average years expected to be recognized over	1 year 3 months 18 days
Weighted Average Grant Date Fair Value Price
Granted \| $ / shares	$ 9.17
Vested \| $ / shares	$ 9.17

XML 51 R41.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Stock-based compensation expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Stock-Based Compensation expense
Total stock based compensation for options granted	$ 942,108	$ 1,339,410	$ 2,118,693	$ 2,843,636
General and administrative
Stock-Based Compensation expense
Total stock based compensation for options granted	448,880	954,241	1,291,159	2,067,352
Research and development
Stock-Based Compensation expense
Total stock based compensation for options granted	$ 493,228	$ 385,169	$ 827,534	$ 776,284

XML 52 R42.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Additional information (Details) - USD ($) $ / shares in Units, $ in Millions	6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Stock-Based Compensation
Unrecognized compensation costs	$ 4.8
Weighted-average amortization period	1 year 3 months 18 days
Weighted average grant date fair value of options granted	$ 5.32	$ 4.78
Stock options granted to consultant for future services	225,000
2016 Plan
Stock-Based Compensation
Number of common stock authorized	291,667
Common shares were available for future grants	147,041
2019 Plan
Stock-Based Compensation
Number of common stock authorized	4,709,277
Common shares were available for future grants	1,294,956

XML 53 R43.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details)	1 Months Ended		3 Months Ended			6 Months Ended
Commitments and Contingencies (Details)	Dec. 31, 2020 USD ($)	Oct. 31, 2020 ft²	Mar. 31, 2021 USD ($)	Dec. 31, 2020	Mar. 31, 2020 USD ($)	Mar. 31, 2021 USD ($)	Mar. 31, 2020 USD ($)
Commitments and Contingencies
Lease agreement term		10 years
Option to extend				true
Initial extension term of lease		10 years
Option to terminate				true
Additional right to extend term		5 years
Lease area \| ft²		14,189
Prepaid rent						$ 300,000
Security deposit paid						300,000
Rent			$ 30,000		$ 20,000	$ 60,000	$ 40,000
Minimum
Commitments and Contingencies
Base rent	$ 71,000
Maximum
Commitments and Contingencies
Base rent	$ 78,000

XML 54 R44.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details) - USD ($)	Apr. 26, 2021	May 01, 2021
Minimum
Subsequent Event [Line Items]
Base rent payable per month		$ 71,000
Maximum
Subsequent Event [Line Items]
Base rent payable per month		$ 78,000
Subsequent Event
Subsequent Event [Line Items]
Common stock issued for cash (in shares)	9,200,000
Stock Issued During Period, Shares, New Issues, Additional Shares	1,200,000
Shares Issued, Price Per Share	$ 5.00

EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 57 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 58 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 94 280 1 false 23 0 false 6 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://neubase.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Consolidated Balance Sheets Sheet http://neubase.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://neubase.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Condensed Consolidated Statements of Operations Sheet http://neubase.com/role/StatementCondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 00300 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://neubase.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 00400 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://neubase.com/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 10101 - Disclosure - Organization and Description of Business Sheet http://neubase.com/role/DisclosureOrganizationAndDescriptionOfBusiness Organization and Description of Business Notes 7 false false R8.htm 10201 - Disclosure - Significant Accounting Policies Sheet http://neubase.com/role/DisclosureSignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 10301 - Disclosure - Liquidity Sheet http://neubase.com/role/DisclosureLiquidity Liquidity Notes 9 false false R10.htm 10401 - Disclosure - Other Prepaid Expenses and Other Current Assets Sheet http://neubase.com/role/DisclosureOtherPrepaidExpensesAndOtherCurrentAssets Other Prepaid Expenses and Other Current Assets Notes 10 false false R11.htm 10501 - Disclosure - Equipment Sheet http://neubase.com/role/DisclosureEquipment Equipment Notes 11 false false R12.htm 10601 - Disclosure - Investment Sheet http://neubase.com/role/DisclosureInvestment Investment Notes 12 false false R13.htm 10701 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet http://neubase.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities Accrued Expenses and Other Current Liabilities Notes 13 false false R14.htm 10801 - Disclosure - Fair Value Sheet http://neubase.com/role/DisclosureFairValue Fair Value Notes 14 false false R15.htm 10901 - Disclosure - Stockholders' Equity Sheet http://neubase.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 11001 - Disclosure - Stock-Based Compensation Sheet http://neubase.com/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 16 false false R17.htm 11101 - Disclosure - Commitments and Contingencies Sheet http://neubase.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 11201 - Disclosure - Subsequent Events Sheet http://neubase.com/role/DisclosureSubsequentEvents Subsequent Events Notes 18 false false R19.htm 20202 - Disclosure - Significant Accounting Policies (Policies) Sheet http://neubase.com/role/DisclosureSignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://neubase.com/role/DisclosureSignificantAccountingPolicies 19 false false R20.htm 30203 - Disclosure - Significant Accounting Policies (Tables) Sheet http://neubase.com/role/DisclosureSignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://neubase.com/role/DisclosureSignificantAccountingPolicies 20 false false R21.htm 30403 - Disclosure - Other Prepaid Expenses and Other Current Assets (Tables) Sheet http://neubase.com/role/DisclosureOtherPrepaidExpensesAndOtherCurrentAssetsTables Other Prepaid Expenses and Other Current Assets (Tables) Tables http://neubase.com/role/DisclosureOtherPrepaidExpensesAndOtherCurrentAssets 21 false false R22.htm 30503 - Disclosure - Equipment (Tables) Sheet http://neubase.com/role/DisclosureEquipmentTables Equipment (Tables) Tables http://neubase.com/role/DisclosureEquipment 22 false false R23.htm 30703 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://neubase.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables Accrued Expenses and Other Current Liabilities (Tables) Tables http://neubase.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities 23 false false R24.htm 30803 - Disclosure - Fair Value (Tables) Sheet http://neubase.com/role/DisclosureFairValueTables Fair Value (Tables) Tables http://neubase.com/role/DisclosureFairValue 24 false false R25.htm 30903 - Disclosure - Stockholders' Equity (Tables) Sheet http://neubase.com/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://neubase.com/role/DisclosureStockholdersEquity 25 false false R26.htm 31003 - Disclosure - Stock-Based Compensation (Tables) Sheet http://neubase.com/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://neubase.com/role/DisclosureStockBasedCompensation 26 false false R27.htm 40101 - Disclosure - Organization and Description of Business - Additional Information (Details) Sheet http://neubase.com/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails Organization and Description of Business - Additional Information (Details) Details 27 false false R28.htm 40201 - Disclosure - Significant Accounting Policies - Marketable Securities (Details) Sheet http://neubase.com/role/DisclosureSignificantAccountingPoliciesMarketableSecuritiesDetails Significant Accounting Policies - Marketable Securities (Details) Details 28 false false R29.htm 40202 - Disclosure - Significant Accounting Policies - Potentially dilutive securities outstanding (Details) Sheet http://neubase.com/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesOutstandingDetails Significant Accounting Policies - Potentially dilutive securities outstanding (Details) Details 29 false false R30.htm 40301 - Disclosure - Liquidity (Details) Sheet http://neubase.com/role/DisclosureLiquidityDetails Liquidity (Details) Details http://neubase.com/role/DisclosureLiquidity 30 false false R31.htm 40401 - Disclosure - Other Prepaid Expenses and Other Current Assets (Details) Sheet http://neubase.com/role/DisclosureOtherPrepaidExpensesAndOtherCurrentAssetsDetails Other Prepaid Expenses and Other Current Assets (Details) Details http://neubase.com/role/DisclosureOtherPrepaidExpensesAndOtherCurrentAssetsTables 31 false false R32.htm 40501 - Disclosure - Equipment (Details) Sheet http://neubase.com/role/DisclosureEquipmentDetails Equipment (Details) Details http://neubase.com/role/DisclosureEquipmentTables 32 false false R33.htm 40502 - Disclosure - Equipment - Additional Information (Details) Sheet http://neubase.com/role/DisclosureEquipmentAdditionalInformationDetails Equipment - Additional Information (Details) Details 33 false false R34.htm 40601 - Disclosure - Investment (Details) Sheet http://neubase.com/role/DisclosureInvestmentDetails Investment (Details) Details http://neubase.com/role/DisclosureInvestment 34 false false R35.htm 40701 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) Sheet http://neubase.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails Accrued Expenses and Other Current Liabilities (Details) Details http://neubase.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables 35 false false R36.htm 40801 - Disclosure - Fair Value - Fair Value Measurements (Details) Sheet http://neubase.com/role/DisclosureFairValueFairValueMeasurementsDetails Fair Value - Fair Value Measurements (Details) Details 36 false false R37.htm 40901 - Disclosure - Stockholders' Equity - Warrants issued and outstanding (Details) Sheet http://neubase.com/role/DisclosureStockholdersEquityWarrantsIssuedAndOutstandingDetails Stockholders' Equity - Warrants issued and outstanding (Details) Details 37 false false R38.htm 41001 - Disclosure - Stock-Based Compensation - Stock options (Details) Sheet http://neubase.com/role/DisclosureStockBasedCompensationStockOptionsDetails Stock-Based Compensation - Stock options (Details) Details 38 false false R39.htm 41002 - Disclosure - Stock-Based Compensation - Key Assumptions Estimate Fair Value Of Stock Options (Details) Sheet http://neubase.com/role/DisclosureStockBasedCompensationKeyAssumptionsEstimateFairValueOfStockOptionsDetails Stock-Based Compensation - Key Assumptions Estimate Fair Value Of Stock Options (Details) Details 39 false false R40.htm 41003 - Disclosure - Stock-Based Compensation - Restricted Stock (Details) Sheet http://neubase.com/role/DisclosureStockBasedCompensationRestrictedStockDetails Stock-Based Compensation - Restricted Stock (Details) Details 40 false false R41.htm 41004 - Disclosure - Stock-Based Compensation - Stock-based compensation expense (Details) Sheet http://neubase.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails Stock-Based Compensation - Stock-based compensation expense (Details) Details 41 false false R42.htm 41005 - Disclosure - Stock-Based Compensation - Additional information (Details) Sheet http://neubase.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional information (Details) Details 42 false false R43.htm 41101 - Disclosure - Commitments and Contingencies (Details) Sheet http://neubase.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://neubase.com/role/DisclosureCommitmentsAndContingencies 43 false false R44.htm 41201 - Disclosure - Subsequent Events (Details) Sheet http://neubase.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) Details http://neubase.com/role/DisclosureSubsequentEvents 44 false false All Reports Book All Reports nbse-20210331.xml nbse-20210331.xsd nbse-20210331_cal.xml nbse-20210331_def.xml nbse-20210331_lab.xml nbse-20210331_pre.xml http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true ZIP 60 0001104659-21-066181-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-066181-xbrl.zip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�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end